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Summary 
Drug resistance is one of the most important reasons for the increase in rates of malarial 
morbidity and mortality. However, even now, there is no effective anti-malarial vaccine 
available. Presently, development of anti-malarials acting by novel pathways is the best option 
to control this disease. The biphenyl urea compound, the lead compound in this study, is a new 
structural class of potent anti-malarial agents. We obtained two subclasses of active 
compounds, termed “sulfnamidomethylen” and “diarylsulfone” during the optimisation to the 
lead compound with computer assistance. The dose-response curves of the two subclasses of 
compounds indicated that they exert their anti-malarial action by different mechanisms. The 
curve of the diarylsulfone showed a biphasic property, while the curve of the 
sulfnamidomethylen is single phasic and very steep.  Then we optimized the 
sulfnamidomethylen compound based on SAR analysis for more potential anti-malarial 
activity. SC81458 was the first candidate compound we obtained, which showed an IC50-value 
of 5.5 nM, and IC99-value of 15.0 nM against Dd2. Then parasitological evaluation showed 
that SC81458 exhibits potent in vitro activity against a wide range of Plasmodium falciparum 
strains, with the IC50-values at the magnitude of nano molar. The study of the property of 
SC81458 against drug resistance selection indicated that there were no Dd2 parasites recovered 
within eight weeks when 108 parasites are exposed to SC81458 at the concentration of 100 nM 
continuously. The stage-specific susceptibility and growth inhibition time course study of 
SC81458 showed that the trophozoites and schizonts are more sensitive to SC81458, showing a 
6 hrs IC50-value of 36.9 nM and 53.7 nM, respectively, while the rings exhibited a 6 hrs IC50-
value of 5124.3 nM. SC81458 can totally kill the trophozoites within 30 minutes at a 
concentration of less than 1 µM, a non-toxic concentration to mammalian cells. Furthermore, 
the in vivo test in the humanized mouse model showed that SC81458 exhibits an excellent in 
vivo activity against both drug sensitive (3D7) and resistant (W2) P. falciparum strains. 
However, SC81458 showed poor bioavailability. Then SC81458 was further optimized for 
better bioavailability. The backup compound SC83288 was obtained, which showed better 
bioavailability (10%) and excellent anti-P. falciparum activity (slightly better than SC81458). 
The parasitological evaluation of SC83288 indicated that SC83288 exhibits the same anti-
Plasmodium property as SC81458 does, which suggested that the two compounds should exert 
their action by the same mechanism.
Zusammenfassung 
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Zusammenfassung 
Medikamentenresistenz ist einer der wichtigsten Gründe für die erhöhte Rate an Malariaerkrankungen 
und -sterblichkeit. Auch heute gibt es keine effektive Impfung gegen Malaria. Zur Zeit ist die 
Entwicklung neuer Antimalariamedikamente die beste Möglichkeit zur Kontrolle dieser Krankheit. Die 
Biphenyl Urea Verbindung, die bedeutendste Verbindung dieser Studie, ist eine neue strukturelle 
Klasse von wirksamen Antimalariamitteln. Wir haben während der Optimierung der aktiven 
Verbindung mittels Computeranalyse die zwei Subklassen „Sulfonamidomethylen” und 
“Diarylsulfon“ gefunden. Die dosisabhängigen Kurven dieser beiden Subklassen der Verbindung legen 
nahe, dass ihrer Antimalariaaktivität unterschiedliche Mechanismen zugrunde liegen. Die Kurve des 
Diarylsulfon ist zweiphasig, während die Kurve von Sulfonamidomethylen einphasig und sehr steil ist. 
Wir haben die Sulfonamidomethylen-Verbindung SAR-abhängig optimiert um eine höhere 
Antimalariaaktivität zu erreichen. SC81458 war der erste erhaltene Kandidatnenwirkstoff und zeigte 
IC50-Werte von 5,5 nM und IC99-Werte von 15,0 nM gegenüber Dd2. Parasitotlogische Evaluationen 
zeigten dann, dass SC81458 eine wirksame in vivo Aktivität mit IC50-Werten im nanomolarem Bereich 
gegen eine große Anzahl von Plasmodium falciparum Stämmen aufweist. In einer Untersuchung über 
die Wirksamkeit von SC81458 gegen das Auftreten von Medikamentenresistenz konnte nachgewiesen 
werden, dass bei der kontinuierlichen Verabreichung von 100 nM SC81458 innerhalb von acht Wochen 
keine Dd2 Parasiten überleben. Weiterhin konnten bei der Messung der stadienspezifischen 
Empfindlichkeit und der zeitabhängigen Wachstumsinhibitions gezeigt werden, dass Trophozoiten und 
Schizonten sensitiver als Ringe gegenüber SC81458 reagieren. So weisen Trophozoiten und Schizonten 
nach sechs Stunden einen IC50-Wert von 36,9 nM beziehungsweise 53,7 nM auf, während für Ringe ein 
IC50-Wert von 5124,3 nM ermittelt wurde. SC81458 kann Trophozoiten innerhalb von 30 Minuten bei 
einer Konzentration von 1 µM, die für Säugetierzellen nicht toxisch ist, vollständig abtöten. Darüber 
hinaus konnte in vivo Tests in humanisierten Mäusemodellen nachgewiesen werden, dass SC81458 eine 
hervorragende in vivo Aktivität gegenüber medikamenten-senstiven (3D7) und –resistenten Stämmen 
(W2) besitzt. SC81458 weist eine schlechte Bioverfügbarkeit auf. Daher wurde SC81458 weiter 
optimiert, um eine bessere Bioverfügbarkeit zu erreichen. Das Backup der Verbindung SC83288 wurde 
verwendet und zeigte eine bessere Bioverfügbarkeit (10%) und exzellente Aktivität gegenüber 
Stämmen von P. falciparum (etwas besser als SC81458). Die parasitologische Evaluation von SC83288 
hat gezeigt, dass SC83288 die gleiche antiplasmodiale Eigenschaft wie SC81458 besitzt. Das bedeutet, 
dass beiden Verbindungen der gleiche Wirkungsmechanismus zugrunde liegen sollte. 
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1 Introduction 
1.1 Malaria 
Malaria is an ancient and deadly infectious disease of humankind, which is caused by 
Plasmodium species (P. falciparum, P. vivax, P. ovale and P. malariae). Nowadays, malaria is 
the most serious tropical disease around the world. As WHO reported in 2008, there were 
about 3 billion people threatened by malaria in 109 countries and territories from South 
America to the Indian peninsula (WHO, 2008). There were around 247 million malaria cases  
worldwide in 2006, of which 91% or 230 million (175-300 million) were due to P. falciparum 
(WHO, 2008). The vast majority of cases (86%) were in the African region, followed by 
South- East Asia (9%) and Eastern Mediterranean regions (3%). The percentage of cases due to 
P. falciparum exceeded 75% in most African countries but only in a few countries outside 
Africa (WHO, 2008). In 2004, malaria was one of the leading causes of death worldwide from 
a single infectious agent (WHO). The disease causes a serious loss of wealth at the same time 
as killing lives. Malaria causes poverty by impeding economic growth, and poverty promotes 
malaria transmission at the same time. With the efforts of many years around the whole world, 
the burden of malaria in some countries is now decreasing. However, malaria still presents a 
terrible burden to public health and malaria control measures still require significant 
improvement. WHO has identified four phases on the path to malaria elimination. By July 
2008, the 109 countries/territories affected by malaria were classified as follows: control (82 
countries/territories), pre-elimination (11 countries/territories), elimination (10 
countries/territories), and the prevention of reintroduction (6 countries/territories). 
Introduction 
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Fig 1.1 Malaria-free countries and malaria-endemic countries in phases of control, pre-
elimination, elimination and prevention of reintroduction, end 2007 (WHO, 2008). 
1.1.1 Life cycle 
The malaria parasite exhibits an extremely complex life cycle involving a cold-blooded insect 
vector (mosquito) and a warm-blooded vertebrate host (human). All four Plasmodium species 
exhibit a similar life cycle with only minor variations.  
During the blood meal of a malaria-infected female Anopheles mosquito, sporozoites from its 
salivary glands are injected into the human host along with anticoagulant-containing saliva. 
Plasmodium is extremely well-adapted to its hosts. In human, a malaria infection can be 
established by a small number of sporozoites (15-40 on average) (Frischknecht et al., 2004; 
Rosenberg et al., 1990). Malaria in humans develops via two phases: an exoerythrocytic 
(hepatic) and an erythrocytic phase. Sporozoites move away with the blood stream from the 
site of injection to the liver, and then infect liver cells. In hepatocytes, each sporozoite 
undergoes extensive replication within a parasite-derived vacuole, essentially walling off the 
parasite from the liver cell cytoplasm. When sporozoites mature into schizonts, the infected 
liver cells rupture and release merozoites. Merosomes appear to play a role in this step to 
ensure safe release of the merozoites directly into the blood circulation (Sturm et al., 2006). 
The time taken to complete this phase is called the prepatient period and varies between 
different plasmodium species. (P. falciparum 8-25 days, P. vivax 8-27 days, P. ovale 9-17 days 
and P. malariae 15-30 days). In the case of P. vivax and P. ovale, some of the sporozoites 
Introduction 
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entering hepatocytes do not develop into exo-erythrocytic schizonts directly, but instead form 
hypnozoites. These small parasite forms (4-5 µm in diameter) can remain dormant in the liver 
for years. At a given point in time, although the triggering signal is still unknown, the 
hypnozoites develop into exo-erythrocytic schizonts, producing thousands of merozoites, 
thereby causing relapses of the disease (Cogswell, 1992).  
Merozoites invade the erythrocytes within minutes after their release and start a second round 
of asexual replication. The process of erythrocytes invasion by the parasite includes a series of 
well-defined and rapid events at the red blood cell (RBC) surface. First, the merozoite interacts 
with the RBC surface and reorients the apical region towards the membrane. The contents of 
the apical organelles (rhoptries and micronemes) are expelled and a moving junction is formed 
between the merozoite and RBC membrane. Finally, the parasite enters a vacuole formed by 
invagination of the RBC membrane and membranes secreted from the parasite. This process is 
completed in a few minutes. However, a huge membranes system is synthesized during the 
short process, which is thought as a potential anti-malarial drug target (Ancelin et al., 2003). 
Three organelles are present on the invasive (apical) end of the parasite (rhoptries, micronemes 
and dense granules). Receptors that mediate invasion of RBCs by merozoites and invasion of 
liver by sporozoites are localized in micronemes, on the cell surface, and in rhoptries. 
Accumulating evidence suggests that these molecules are the major targets of neutralizing 
immune responses (Mahanty et al., 2003). The erythrocyte invasion requires a series of highly 
specific interactions and it is considered to be a very attractive target for drug development. 
Inside the erythrocyte, the parasite develops through different stages (Bannister et al., 2000). P. 
falciparum differs from other human malarial species in that parasitized erythrocytes do not 
remain in the circulating blood for their entire life cycle. After 24-32 hours, when young 
parasites mature from the ring to the trophozoite stage, parasitized erythrocytes adhere to 
endothelial cells in the microcirculation of various organs (termed sequestration). Trophozoites 
mature into schizonts, which eventually rupture and release 16-32 daughter merozoites that 
invade fresh erythrocytes to perpetuate the asexual life cycle (Baruch, 1999; Chen et al., 2000; 
Newbold et al., 1999). The release of merozoites coincides with the sharp increase in body 
temperature during the progression of the disease. This procedure occurs quite synchronously 
and merozoites are released approximately the same time of the day which explains the 
periodicity of the fever paroxysms experienced by the patient (Tuteja, 2007). P. malariae 
exhibits a 72 hrs periodicity, whereas the other three species exhibit 48 hrs cycles. As an 
alternative to the asexual replicative cycle, the parasite can differentiate into sexual forms 
known as macro- or microgametocytes. The gametocytes are large parasites which fill up the 
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erythrocyte, but only contain one nucleus. Ingestion of gametocytes by the mosquito vector 
induces gametogenesis (i.e., the production of gametes) and escape from the host erythrocyte. 
Factors which participate in the induction of gametogenesis include: a drop in temperature, an 
increase in carbon dioxide, and mosquito metabolites. Microgametes, formed by a process 
known as exflagellation, are flagellated forms which will fertilize the macrogamete leading to a 
zygote. The zygote develops into a motile ookinete which penetrates the gut epithelial cells and 
develops into an oocyst. The oocyst undergoes multiple rounds of asexual replication resulting 
in the production of sporozoites. Rupture of the mature oocyst releases the sporozoites into the 
hemocoel (i.e., body cavity) of the mosquito. The sporozoites migrate to and invade the 
salivary glands, where the sporozoites are injected to a new host during blood feeding. The 
infective bite of the mosquito will start a new life cycle (Tuteja, 2007). 
1.1.2 Clinical manifestations  
The patients suffering from malaria showed a wide variety of symptoms, ranging from absent 
or very mild symptoms to severe disease and even death. Actually, malaria is a curable disease 
if diagnosed and treated promptly and correctly, even for severe malaria. The clinical 
manifestation with the development of malaria consists of a cold stage (sensation of cold, 
shivering), a hot stage (fever, headaches, vomiting; seizures in young children) and finally a 
sweating stage (sweats, return to normal temperature, tiredness). The blood stage is responsible 
for the pathology associated with malaria. The intermittent fever paroxyms are due to the 
synchronous lysis of the infected erythrocytes. P. malariae exhibits a 72 hrs periodicity, 
whereas P. falciparum, P. vivax, and P. ovale exhibit 48 hrs cycles. Severe malaria occurs 
when P. falciparum infection is complicated by serious organ failures or abnormalities in the 
patient's blood or metabolism. Seizures, hypoglycemia, and severe anemia are common 
manifestations of severe malaria in children, whereas jaundice, pulmonary edema, and acute 
renal failure are more common in adults. The mortality despite treatment rises to 15–20%. 
Cytoadherence of infected erythrocytes to the brain microvasculature, mediated by the 
members of the P. falciparum erythrocyte membrane protein 1 (PfEMP1) family (Baruch et al., 
1995) is thought to contribute to cerebral malaria and coma (Kirchgatter and Del Portillo, 
2005; Warrell et al., 1990). Meanwhile, lactic acidosis can also be a cause (English et al., 
1996). Lowered oxygen delivery caused by severe anemia and impaired tissue perfusion are 
thought to be responsible for respiratory distress (Marsh and Snow, 1997). The clinical 
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outcome of malaria is complex and depends on many host and parasite factors, which makes a 
better understanding of the disease itself and the biology of the parasite imperative.  
1.2 Anti-malarial drugs 
1.2.1 Anti-malarial drugs in clinical use 
Currently used anti-malarials stem from seven drug classes: 4-Aminoquinolines, 
arylaminoalcohols, 8-aminoquinolines, artemisinins, antifolates, inhibitors of the respiratory 
chain, and antibiotics (Schlitzer, 2008). Although continued attempts to develop a vaccine for 
malaria are ongoing, drugs continue to be the only treatment option today. 
1.2.1.1 Arylaminoalcohols 
This class of anti-malarial drugs includes quinine, mefloquine, halofantrine and lumefantrine. 
The mechanism of action of them seems to be different from that of 4-aminoquinolines. 
However, it still remains not clear. Arylaminoalcohols seem to interfere with the heme 
digestion. As reported, the amplification of pfmdr1 gene contributes to arylaminoalcohol 
resistance, which codes for a transport protein (P. falciparum multidrug resistance 1, PfMDR1) 
located in the membrane of the digestive vacuole. 
1.2.1.1.1 Quinine 
Quinine is the first known effective anti-malarial agent, which is the active ingredient of 
Cinchona bark, a tree found in South America. Quinine acts as a blood schizonticide although 
it also has gametocytocidal activity against P. vivax and P. malariae. Because it is a weak base, 
quinine is concentrated in the food vacuoles of parasites. The action mechanism of quinine still 
not clear. It is said to act by inhibiting heme polymerase, thereby allowing accumulation of its 
cytotoxic substrate, heme. However, the research of Chou and Fitch indicated that quinine 
showed no inhibition activity against heme polymerase (Chou and Fitch, 1993). Quinine is less 
effective and more toxic than chloroquine. The typical syndrome of quinine side effects is 
called cinchonism, which consists of ringing in the ears, headache, nausea and disturbed vision. 
Tinnitus, decreased auditory acuity and vertigo are caused by quinine through functional 
impairment of the eighth nerve. Visual symptoms include blurred vision, disturbed colour 
perception, photophobia, diplopia, night blindness, and rarely, even blindness. Gastrointestinal 
symptoms consist of nausea, vomiting, abdominal pain and diarrhoea. Rashes, sweating, 
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angioedema may be seen. Excitement, confusion, delirium are also seen in some patients. 
Coma, respiratory arrest, hypotension, and death can occur with over dosage. Quinine can also 
cause renal failure. Massive hemolysis and hemoglobinuria can occur, especially in pregnancy 
or on repeated use. Hypoprothrombinemia, agranulocytosis are also reported. Quinine has little 
effect on the heart in therapeutic doses and hence regular cardiac monitoring is not needed. 
However it can cause hypotension in the event of overdose. Quinine reduces the excitability of 
the motor end plate and thus antagonises the actions of physostigmine. It can cause respiratory 
distress and dysphagia in patients of myasthenia gravis. Quinine stimulates insulin secretion 
and in therapeutic doses it can cause hypoglycemia. This can be more severe in patients with 
severe infection and in pregnancy. Hypoglycemia in malaria may go unnoticed and could even 
cause death. Therefore, it is advisable to monitor blood glucose levels at least once in 4-6 hrs 
while quinine is administered, especially in severe infection and in pregnancy. Hypersensitivity 
in the form of rashes, angioedema, visual and auditory symptoms is indications for stopping 
the treatment. It is contraindicated in patients with tinnitus and optic neuritis. It should be used 
with caution in patients with atrial fibrillation. Hemolysis is indication for immediately 
stopping the drug. It is also contraindicated in patients suffering from myasthenia gravis. 
Quinine still is used in the treatment of severe falciparum malaria in areas with known 
resistance to chloroquine. 
1.2.1.1.2 Mefloquine 
Mefloquine was developed as a novel anti-malarial drug against multidrug resistant falciparum 
(Trenholme et al., 1975) , which was born during the Vietnam war to protect the American 
soldiers from malaria (Horton, 1988). Mefloquine has been found to produce swelling of the P. 
falciparum food vacuoles. It was believed to act by forming toxic complexes with free heme 
that damage membranes and interact with other plasmodial components. It showed an activity 
against the blood forms of falciparum malaria, including the chloroquine resistant types. The 
side effects of mefloquine consist of nausea, vomiting, abdominal pain and dizziness. Less 
frequently it can cause nightmares, sleeping disturbances, dizziness, ataxia, sinus bradycardia, 
sinus arrhythmia, postural hypotension, and an 'acute brain syndrome' consisting of fatigue, 
asthenia, seizures and psychosis. Drug resistance to mefloquine was developed very rapidly by 
the falciparum parasites (Horton, 1988; Ridley, 2002). 
1.2.1.1.3 Halofantrine 
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Halofantrine was developed in the 1960s by the Walter Reed Army Institute of Research 
(Horton, 1988). More than 250 000 compounds were tested in this project. Two important 
compounds emerged after the screen – mefloquine and halofantrine. Both of them are 
structurally related to quinine. Its mechanism of action still is not known, which may be 
different from quinine, and mefloquine (Horton, 1988). This synthetic anti-malarial is effective 
against multi drug resistant (including mefloquine resistant) P. falciparum malaria. As reported, 
halofantrine could cause cardiotoxicity (Monlun et al., 1995). 
1.2.1.1.4 Lumefantrine 
Lumefantrine, discovered in the Peoples’ Republic of China, is an arylamino alcohol in the 
same general group as mefloquine and halofantrine. It is active against all human malaria 
parasites, which has been used clinically in China for several years. Even the multidrug 
resistant P. falciparum strains also are sensitive to lumefantrine. Lumefantrine usually is used 
combinated with artemether. This combination is currently used under the brand name 
Riametm or Co- Artem™, which is the first fixed combination of an artemisinin derivative and 
a second unrelated anti-malarial compound. The anti-malarial activity of lumefantrine is lower 
than halofantrine. However, lumefantrine do not cause any cardiac side effect as halofantrine 
does. It is a highly lipophilic drug. The bioavailability of lumefantrine critically depends on 
coadministration with fats.  
1.2.1.2 4-Aminoquinolines 
4-Aminoquinolines anti-malarial drugs include chloroquineand amodiaquine, which have been 
used for clinical malaria therapy more than 60 years. Resistance against 4-aminoquinolines 
results from a mutation of K76T in the gene of a transport protein (chloroquine resistance 
transporter, CRT) located in the membrane of the digestive vacuole. It pumps 4-
aminoquinolines outside from the digestive vacuole and reduce the concentration of drugs 
inside the digestive vacuole. 
1.2.1.2.1 Chloroquine 
Chloroquine is the prototype anti-malarial drug with a long clinical use history. It was used as 
an anti-malarial drug for decades in all malaria-endemic areas and is still used as a first-line 
treatment in central America and parts of Africa for P. falciparum malaria. Even now, 
chloroquine is still the anti-malarial agent that is cheapest, time tested, easiest to administer 
and has fewest side effects. It showed a very significant effect against erythrocytic forms of P. 
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vivax, P. ovale and P. malariae, sensitive strains of P. falciparum and gametocytes of P. vivax. 
It was widely used to treat all types of malarial infections. The most spectacular characteristic 
of chloroquine is its capacity to concentrate itself from nanomolar levels outside the parasite to 
millimolar levels in the digestive vacuole of the intraerythrocytic trophozoite. However, the 
action mechanism of chloroquine still is not clear even now. The most common idea on this is 
that chloroquine could accumulate within the food vacuoles of the parasite, where the 
haemoglobin is digested into its component peptides. The peptides are exported from the DV 
and leave behind ferriprotoporphyrin IX (FPIX), also known as haem, which is potentially 
toxic to the parasite. The toxicity of hame is circumvented by incorporation of FPIX dimers 
into an inert, crystalline substance, hemozoin. Chloroquine is thought to form complexes with 
toxic hame moietie and interfere with the detoxification mechanism. (Ginsburg et al., 1999; 
Pagola et al., 2000; Sullivan et al., 1998). The side effects of chloroquine include dizziness, 
headache, diplopia, disturbed visual accomodation, dysphagia, nausea, malaise, pruritus of 
palms, visual hallucinations, confusion, and occasionally frank psychosis. These side effects do 
not warrant stoppage of treatment. Chloroquine resistance (CQR) is a important reason for the 
wide spread of malaria, which was first reported in Southeast Asia and South America (Payne, 
1987; Ridley, 2002). In the late 1950's, resistance to chloroquine was noted on the Thai-
Cambodian border and in Colombia. All endemic areas in South America were affected by 
1980 and almost all in Asia and Oceania by 1989. In Africa, chloroquine resistance was first 
documented in the east in 1978. Resistance spread to the central and southern parts of the 
continent before arriving in west Africa in 1983. By 1989, chloroquine resistance was 
widespread in sub-Saharan Africa (Wongsrichanalai et al., 2002). Sulfadoxine-pyrimethamine 
or a combination of chloroquine and sulfadoxine-pyrimethamine were used as first-line anti-
malarial drug in chloroquine resistance region for many years (Wongsrichanalai et al., 2002). 
As reported recently, the chloroquine resistance mutation in the parasite had nearly disappeared 
after the stop of the use of chloroquine in this region, and studies of adults hinted that 
chloroquine could clear the parasite again (Vogel, 2006). 
1.2.1.2.2 Amodiaquine 
Amodiaquine is structurally related to chloroquine and has been widely used as anti-malarial 
drug around for 60 years. In the mid-1990s, amodiaquine was pushed by WHO in the treatment 
of malaria. As reported, amodiaquine showed good safety and efficacy in children with 
uncomplicated malaria when it is used alone or in combination with artesunate or with 
sulfadoxine-pyrimethamine (D'Alessandro and ter Kuile, 2006). Amodiaquine is a low cost 
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anti-malarial drug, which means it could be widely used in poor countries. Amodiaquine use 
has been limited since the mid 1980s after it was linked causally to the occurrence of 
occasional agranulocytosis in adult travellers taking the drug prophylactically. But because 
amodiaquine retains a high degree of efficacy against all but the most highly chloroquine-
resistant strains, there has been a recent increase in its use. Actually, artesunate-amodiaquine is 
used as first-line treatment for children with uncomplicated malaria in some African countries. 
Amodiaquine can cause annoying pruritus, agranulocytosis and liver damage. 
1.2.1.3 8-Aminoquinolines 
1.2.1.3.1 Primaquine 
Primaquine, the only 8-aminoquinoline currently in use, is a highly effective anti-malarial 
agent, which showed activity against the gametocytes of all plasmodia specially. Thereby, it 
can prevent spread of the disease to the mosquito from the patient. Primaquine is also effective 
against the dormant tissue forms of P. vivax and P. ovale malaria. Until now, primaquine is still 
the only anti-malarial drug licensed for the radical cure (or antirelapse therapy) of P. vivax 
infections. Primaquine showed an excellent activity against the asexual blood forms of the 
parasite and therefore it is always used in combination with a blood schizonticide. 
Furthermore, primaquine has shown to be effective in the chemoprophylaxis of P. falciparum 
infections. The action mechanism of primaquine is not well understood. It may exert its anti 
malaria action by generating reactive oxygen species (Thornalley et al., 1983) or by disrupting 
intracellular transport processes such as secretion and receptor recycling (Hiebsch et al., 1991). 
Primaquine may cause occasional epigastric distress and abdominal cramps at larger dose, 
which can be minimised by taking the drug with a meal. In some cases, mild anemia, cyanosis 
and methemoglobinemia may also be seen. Severe methemoglobinemia can occur rarely in 
patients with deficiency of NADH methemoglobin reductase. Granulocytopenia and 
agranulocytosis are rare complications. Patients with deficiency of Glucose 6-phosphate 
dehydrogenase will develop hemolytic anemia on taking usual doses of primaquine (Alving et 
al., 1956). This problem is restricted to certain sections of the population. The drug should be 
stopped when signs of hemolysis and anemia are observed. 
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1.2.1.4 Artemisinines 
Li Shizhen, a great Chinese herbalist of 400 years ago, wrote in his Ben Cao Gang Mu that 
chills and fever of malaria can be combated by qing hao (Artemisia annua shrub) preparations, 
which has been used for centuries in traditional Chinese medicine to cure fevers. Artemisinin 
was first isolated in 1971 by Chinese chemists. Artemisinin is called as Qing Hao Su in 
Chinese, which means the active element of qin hao. Artemisinin and semisynthetic 
derivatives, including artesunate, artemether and dihydroartemisinin, are short-acting anti-
malarial agents that kill parasites more rapidly than conventional anti-malarials, and are active 
against both the sexual and asexual stages of the parasite cycle. Furthermore, artemisinins kill 
all species of plasmodium that infect humans. Artemisinin fever clearance time is shortened to 
32 hrs as compared with 2-3 days with older agents (German and Aweeka, 2008). Artemisinin 
derivatives are the most important new class of anti-malarials and are in widespread use. 
Artemisinin is chemically unrelated to existing anti-malarial agents and thus no traditional drug 
resistant parasite strain cross-resistant to artemisinin. However, the in vivo half lives of theses 
drugs are very short. Recrudescence of parasites is seen in patients undergoing short course 
treatment, unless it is combined with another long acting drug, such as mefloquine. The action 
mechanism of artemisinin still is not clear. There many different hypothesises on it. As 
reported, artemisinin may exert its effect by interfering with the plasmodial hemoglobin 
catabolic pathway and inhibition of heme polymerization (Pandey et al., 1999). Another study 
indicated that the activity of artemisinin might be propagated by interactions between the 
endoperoxide bridge of the drug and heme-iron, produced during hemoglobin degradation 
inside the DV. This iron has been proposed to generate free radicals that alkylate and oxidize 
proteins and lipids within infected RBCs (Kannan et al., 2005). This hypothesis is consistent 
with the finding that artemisinin activity can be potentiated by oxygen and oxidizing agents 
and attenuated by reducing agents. However, the study on the stage activity of artemisinin 
indicated that artemisinins are effective against ring-stage parasites, which do not seem to have 
high concentrations of heme. One proposed that artemisinins are activated via reductive 
cleavage of the peroxide bond by intracellular iron–sulfur redox centers, which are common to 
Plasmodium enzymes, and that alkylation of these enzymes could result in parasite death. The 
binding analysis between parasite lysates and radiolabeled artemisinin identified several 
interacting proteins, indicating that parasite death might result from the alkylation and 
inactivation of parasite proteins. The potential protein target of artemisinins include cysteine 
proteases, proteins of the electron transport chain, translationally controlled tumor protein and 
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PfATP6, a SERCA-type Ca2+ATPase. PfATP6 has received the most attention because its 
activity in transfected X. laevis oocytes is abolished by artemisinin but is unaffected by other 
anti-malarials. As further reported, an L263E point mutation in PfATP6 can abolish inhibition 
by artemisinins. The study on allelic exchange indicated that L263E mutants exhibit a higher 
IC50-value than the wild-type control. However, additional work indicated that artemisinin 
derivatives cause early disruption of the parasite DV and do not seem to affect the structure of 
the endoplasmic reticulum, where PfATP6 is presumably located. With the work on the 
modification of artemisinin, a series of artemisinin derivatives showed excellent anti-malarial 
activity and better ADMET properties. There were few side effects in experimental animals 
when some derivatives were used at a very high dose, which include neurotoxicity and electro-
cardiographic and haematological abnormalities (Brewer et al., 1994). Artemisinin-based 
combination therapies (ACTs) are a new generation of anti-malarial drugs, which have been 
used for around a decade.  
1.2.1.5 Antifolates  
1.2.1.5.1 Chloroguanide (Proguanil) 
Chlorproguanil is a biguanide prodrug that is metabolized to chlorcycloguanil, an specific 
inhibitor of the P. falciparum DHFR, by which it exerts its anti-malarial action (Hastings and 
Sibley, 2002).This drug was developed by British anti-malarial research in 1945. It has causal 
prophylactic and suppressive activity against P. falciparum and cures the acute infection. It is 
also effective in suppressing the clinical attacks of vivax malaria. However it is slower 
compared to 4-aminoquinolines. At the prophylactic doses, it produces occasional nausea and 
diarrhoea. 
1.2.1.5.2 Dapsone  
Dapsone is a sulfa drug, killing malarial parasites by inhibiting the enzyme dihydropteroate 
synthase (DHPS) (Triglia et al., 1997) with an elimination half-life of about 30 hrs. It has been 
combined with chlorproguanil (which has an elimination half-life of about 20 hrs). Dapsone 
can cause methaemoglobinaemia and haemolysis in individuals with glucose-6-phosphate 
dehydrogenase deficiency. This limited the use of dapsone in the treatment of malaria. 
1.2.1.5.3 Pyrimethamine and Sulphadoxine  
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Both of the two drugs are antifolate anti-malarial drugs. They will be discussed in the 
“combination therapy” section later. 
1.2.1.6 Antibiotics 
1.2.1.6.1 Tetracyclines 
Tetracyclines are a group of effective anti-malarials, which act relatively slowly. They are 
always used in combination with a faster acting drug like quine to treat malaria and for anti-
malarial chemoprophylaxis (Dahl et al., 2006). One of the first antibiotics to come into use in 
human beings, these drugs have stood the test of time and are continuing to be useful in 
treating a broad range of infections, including malaria. Tetracyclines are bacteriostatic agents, 
supposedly acting by inhibiting protein synthesis by binding to the 30 S ribosome subunit. The 
anti-malarial mechanism of action of tetracyclines remains undefined. They maybe exert their 
anti-malarial action by inhibiting the production of proteins encoded by the apicoplast genome, 
leading to a subsequent loss of apicoplast function. So tetracyclines exhibit a delayed but 
potent anti-malarial effect, especially in the treatment of drug-resistant P. falciparum malaria. 
(Dahl et al., 2006). The adverse effects mainly include gastrointestinal irritation, nausea, 
vomiting, diarrhoea, photosensitivity, hepato-toxicity, aggravation of uremia, hypersensitivity 
reactions, staining of the teeth if used in young children and pregnant women etc. They are 
contraindicated in children below the age of 8 years and in pregnant women because of their 
adverse effects on bones and teeth.  
1.2.1.7 Inhibitors of the respiratory chain 
1.2.1.7.1 Atovaquone  
As a synthetic hydroxynaphthoquinone developed in the early 1980s, atovaquone showed 
potential activity against Plasmodium (as well as Toxoplasma and Pneumocystis carinii). It is a 
structural analogue of coenzyme Q and exerts its anti-malarial action by collapsing the 
organellar membrane potential, thus arresting parasite respiration and essential pyrimidine 
biosynthesis. This effect of atovaquone was caused by its inhibition activity against 
cytochrome b in complex III of the chain. The human mitochondria employ a CoQ10 complex 
(i.e. one carrying 10 isoprene units on the aromatic ring), which differs from the CoQ8 type 
found in the parasite. So atovaquone can kill Plasmodium parasites in vivo without affecting 
human mitochondria. However, cytochrome bc1 mitochondrial complex, the target of 
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atovaquone, is subject to a high frequency of pre-existing mutations, which means atovaquone 
is very easy to be resistant by parasites through mutation in the target gene. As reported, one in 
three patients treated with atovaquone monotherapy in Thailand already carried parasites 
resistant to the drug (Vaidya, 2001). Atovaquone may cause rash, fever, vomiting, diarrhoea 
and head ache. Safety in pregnancy, lactation, children, and elderly is yet to be established. 
1.2.2 Anti-malarial drugs combination in clinical use 
Combination therapy with anti-malarial drugs is the simultaneous use of two or more blood 
schizontocidal drugs with independent modes of action and different biochemical targets in the 
parasite (WHO, 2006). Combination chemotherapy showed excellent efficacy in the treatment 
of tuberculosis, HIV disease and cancer. The reasons for the combination of anti-malarial drugs 
mainly lie in three aspects. Firstly, drug combination can decrease the risk of multidrug 
resistant parasites arising during therapy, which are the biggest therapeutic challenge to health 
care in most malaria-endemic areas. Multidrug resistance has been reported from most parts of 
the world and traditional monotherapy is either ineffective or less effective. Therefore, rational 
anti-malarial combination chemotherapy is widely advocated. Theoretically, if drug resistance 
develops by spontaneous point mutation or gene amplification, the frequency of resistance to 
both of the two drugs with different modes of action should be a product of the two mutation 
frequencies. As the drug resistance frequencies very low in malaria parasites, it seems unlikely 
that a parasite could develop spontaneously resistant to two unrelated drugs. Secondly, drug 
combination can increase anti-malarial efficacy. Thirdly, drug combination can shorten 
duration of treatment, hence increasing compliance. Furthermore, the pharmacokinetic 
properties of the combinated drugs should also match well. Otherwise, the anti-malarial 
efficacy of combination drugs would not be increased significantly, even serious advers effect 
occurred. The successful ACTs are as follows: 
1.2.2.1 Artemisinin-based combination therapies (ACTs) 
Artemisinin-based combination therapies (ACTs) are the new generation of anti-malarial drugs, 
which have been used around for a decade. Artemisinin showed an excellent activity against 
malarial parasites and can kill the parasites in vivo rapidly. However, the in vivo half life of 
artemisinin is really short, which means the more risk of parasite recrudescence. So 
artemisinins are combined with one of several longer-acting drugs, such as amodiaquine, 
mefloquine, sulfadoxine/pyrimethamine and lumefantrine, which can eliminate the residual 
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malarial parasites (German and Aweeka, 2008). Artemisinin-based combination therapies are 
currently recommended by WHO for the treatment of uncomplicated P. falciparum malaria 
(WHO, 2008). The clinical use of ACTs showed that they can improve cure rates, reduce the 
development of resistance and they might decrease transmission of drug-resistant parasites. 
The mainly used ACTs are as follows: 
1.2.2.1.1 Artemether-Lumefantrine (CoartemTM)  
Lumefantrine is structurally similar to mefloquine and halofantrine, and no neurotoxicity and 
cardiotoxicity was seen during animal toxicology studies in preclinical development. Coartem 
is now registered widely as an approved anti-malarial drug, which is pushed by WHO in 
tropical Africa. The rapid clinical parasite clearance and the theoretically excellent property 
against drug resistance selection make this combination an attractive treatment for malaria, 
despite its cost. It is the only fixed-dose artemisinin-containing formulation registered after 
internationally recognised guidelines. It seemed safe and well tolerated in children as well as in 
adults. There is considerable mismatch in elimination half-lives of artemether and lumefantrine. 
Efficacy of the six-dose regimen is adequate, which has given satisfactory cure rates, but 
inferior to the combination of artesunate-mefloquine in Thailand.  
1.2.2.1.2 Artesunate-mefloquine 
A 3-day regimen of artesunate-mefloquine has been the preferred treatment for malaria in 
Thailand. It is safe, well tolerated and highly effective. In Thailand, malaria incidence and 
mefloquine resistance have decreased since this combination has come into use. Disadvantages 
of this regimen include its price and the pharmacokinetic mismatch. 
1.2.2.1.3 Artesunate-Amodiaquine 
It showed a better efficacy than amodiaquine alone and is well tolerated. However, the 
pharmacokinetic properties of the two drugs do not match well. WHO recommends this 
regimen for treatment of uncomplicated falciparum malaria in African children. Indeed, in 
some African countries, artesunate-amodiaquine is considered as first-line treatment for 
children with uncomplicated malaria.  
1.2.2.1.4 Dihydroartemisinin–piperaquine (Artekin™) 
Piperaquine, a bisquinoline anti-malarial drug, is developed by the group from China and 
France in the 1960s. The combination of dihydroartemisinin-piperaquine was developed as 
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Artekin™ to provide a cheap and reasonably well-tolerated, short-course treatment for P. 
falciparum, which showed a high cure rate against drug-resistant parasites. It has been widely 
used in controlled clinical trials in South-East Asia, with excellent clinical efficacy against 
chloroquine-resistant parasites. However, there is considerable mismatch in elimination half-
lives of piperaquine (23 days) and dihydroartemisinin (1 hrs), which might develop resistance 
rapidly.  
Theoretically, artemisinin-containing combinations might not only improve cure rates but also 
delay the development of resistance. Furthermore, artemisinin-containing combinations might 
also decrease the transmission of drug-resistant parasites by reducing the number of 
gametocytes carried by patients. Based on available safety and efficacy, ACTs should be 
pushed as active anti-malarial drugs. Widespread use of these drugs could roll back malaria. 
However, the cost of ACTs treatment is more expensive than conventional anti-malarial drugs, 
which may be a hindrance in poor communities.  
1.2.2.2 Atovaquone-Proguanil (MalaroneTM) 
Atovaquone acts by inhibiting the parasite’s mitochondrial complex bc1 and disrupting the 
membrane potential. Because of the high frequency of resistant mutants associated with 
atovaquone monotherapy, it was combined with proguanil (a biguanide acting on DHFR) based 
on promising results of in vitro experiments, which showed synergistic activity (Canfield et al., 
1995). This combination, registrated as Malarone™, is approved for both treatment and 
prophylaxis of malaria. It showed high efficacy in the treatment of uncomplicated malaria 
caused by Plasmodium falciparum, even by chloroquine-resistant or multidrug-resistant strains. 
As atovaquone is fat-soluble, the daily dose should be taken with food or milk. 
1.2.2.3 Pyrimethamine-Sulphadoxine (FansidarTM)  
Fansidar is a very useful adjunct in the treatment of uncomplicated, chloroquine resistant, P. 
falciparum malaria. Pyrimethamine exerts its killing action by the inhibition to dihydrofolate 
reductase of malaria parasites and thereby blocks the biosynthesis of purines and pyrimidines, 
which are essential for DNA synthesis and cell multiplication. Then the parasites were killed in 
schizont stage in erythrocytes and liver. It has been used as a prophylactic agent against 
malaria since 50 years ago. Sulfadoxine inhibits the utilisation of para-aminobenzoic acid in 
the synthesis of dihydropteroic acid. The combination of pyrimethamine and sulfadoxine offers 
two step synergistic blockade of plasmodial division. Other than the action mechanism, the 
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ADMET properties of the two components also match well. Pyrimethamine has good oral 
bioavailability. It’s slowly but completely absorbed after oral administration and is eliminated 
slowly, with a plasma half-life of 80-95 hours. Sulfadoxine is rapidly absorbed from the gut 
and is bound to plasma proteins. This drug is metabolised in the liver and is excreted in the 
urine. Sulfadoxine is a long acting sulfonamide with a half-life of 7-9 days. After the 
emergence of chloroquine resistance, sulfadoxine-pyrimethamine was the most commonly used 
anti-malarial drug in almost all endemic areas between the 1960s and the 1980s. Now, with the 
emergence of resistance to this drug, it is mainly used in Africa. The dominant reasons for the 
continue use of this drug are that it is a single-dose treatment and it’s cheaper than the 
alternatives. Pyrimethamine can cause occasional skin rashes and depression of hematopoiesis. 
Excessive doses can produce megaloblastic anemia. Sulfonamides can cause agranulocytosis, 
aplastic anemia, hypersensitivity reactions, liver dysfunction, anorexia, vomiting and acute 
hemolytic anemia. This drug is contraindicated in patients with known hypersensitivity to 
sulfa, infants below 2 months of age, patients with advanced renal disease and first and last 
trimesters of pregnancy.  
The reasons why combination regimens do not always work  
Firstly, the genome of P. falciparum is more complexe than bacteria, which means it is easier to 
produce drug resistance mutants. Furthermore, the eukaryotic falciparum genome contains 
more complex mechanisms that might mediate drug resistance than does the bacterium. For 
example, there are so many drug resistance transporters in P. falciparum, such as PfMDR1 and 
PfCRT. And there must be still a lot of unknown drug resistance transporters in the P. 
falciparum parasites. They pump out the anti-malarial drugs and cause the concentration 
decrease of drugs around their targets. Even one transporter can pump diverse anti-malarial 
drugs, such as PfMDR1, a well known transporter, which can transport aminoquinolines 
(chloroquine and amodiaquine and mefloquine and halofantrine) and confer the resistance to 
those drugs. Furthermore, the drug-resistance-inducing property of combination therapy 
depends on the area of the parasite’s genome targeted by the drugs. Combination therapy 
would show a poor effectiveness when the targets genes of the combined drugs are subjected to 
high frequency mutation areas. And multidrug-resistant parasites often develop resistance to 
unrelated compounds at rates far higher than those noted for parasites still sensitive to most 
drugs (Rathod et al., 1997). Actually, there is no combination regimen ideal in all aspects, 
including matched action mechanisms and pharmacokinetic properties, toxicity tolerance, drug 
resistance induce property, drug-drug interaction and in vivo half life. 
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1.2.3 Drugs in clinical studies for future chemotherapy 
1.2.3.1 Tafenoquine 
The 8-aminoquinoline tafenoquine, a more lipophilic derivative of primaquine, showed 
excellent activity against blood and liver stage parasites. It has also been used for the 
elimination of P. vivax hypnozoites and the therapy of acute vivax malaria. Tafenoquine 
showed a clinical protective efficacy of 86–100%. The action mechanism of tafenoquine still 
remains unclear. It exhibits primaquine-like effect on the respiratory chain and quinine-like 
activity on heme polymerization. This is consistent with the activity against asexual blood 
stages. As reported, tafenoquine still cause hemolysis in glucose-6-phosphate-dehydrogenase-
deficient humans. However, it is better tolerated than primaquine. 
1.2.3.2 AQ-13 
AQ-13 is a chloroquine derivative with a shortened side chain. However, it is active against 
chloroquine-resistant parasites. There still is a significant correlation between the susceptibility 
of different isolates toward AQ-13 and CQ, indicating the cross-resistance between CQ and 
AQ-13. At high doses, AQ-13 exhibited more toxicity in rats than chloroquine.  
1.2.3.3 Ferroquine 
Ferroquine showed activity against different chloroquine-sensitive and chloroquine-resistant 
strains, which bears a ferrocenyl moiety in the side chain. The lipophilic ferrocenyl moiety 
may be responsible for the activity against chloroquine-resistant strains, which make 
ferroquine does not fit into the substrate binding site of the chloroquine resistance transporter. 
As reported, this drug is about to enter clinical development . 
1.2.3.4 T3 
After the invasion into erythrocyte, parasites produce a huge amount of membrane system 
through the phospholipids metabolism pathway. This class of bis-cationic compounds was 
developed targeting this pathway. T3, an excellent bis-cationic candidate compound, exhibited 
IC50-values between 2.3 and 6.3 nM against different chloroquine-sensitive and chloroquine-
resistant parasite strains and an ED50 of 0.44 µM when administered i.p. in rodent model. It is 
about to enter clinical development. However, T3 showed a poor bioavailability. As reported, 
an in vivo active prodrug has been developed, with a bioavailability of about 16% in rats. 
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1.2.3.5 Fosmidomycin 
Fosmidomycin is an excellent inhibitor of plasmodium falciparum 1-desoxy-Dxylulose-5-
phosphate reductoisomerase (DXR), which is responsible for mevalonate-independent 
isoprenoid biosynthesis. This pathway is essential for the parasites and does not exist in 
humans, which means it is a potential target for anti-malarial drug development. 
Fosmidomycin showed in vitro anti-malarial activity against four laboratory strains with IC50-
values of 390–940 nM. There is no cross-resistance between fosmidomycin and other 
conventional anti-malarials. Fosmidomycin is a rapid acting anti-malarial agent, with a PCT50 
of 21 hrs and a PCT90 of 28 hrs in clinical patients. The cure rate of 100% was observed at day 
seven. However, the recrudescence rate in non-immune patients was unacceptably high when 
fosmidomycin was used alone. Now, the combination of fosmidomycin with clindamycin has 
entered clinical phase development. 
1.2.3.6 Isoquine  
Isoquine was discovered by reseachers from the University of Liverpool through optimization 
of amodiaquine. The toxicity of amodiaquine, such as hepatotoxicity and agranulocytosis, was 
bypassed but the antiparasitic activity was retained. Isoquine is scheduled to enter Phase I trials 
in March 2006. 
1.2.4 Anti-malarial drugs combination in clinical studies 
As no presently used combination regimen is ideal in all aspects, novel combinations of anti-
malarial drugs are being developed. Some of them have entered the clinical trial phase.  
1.2.4.1 Chlorproguanil-dapsone-artesunate (Lapdap™) 
The combination of chlorproguanil and dapsone was developed as an effective and cheap anti-
malarial agent in 2003, which used as substitution for sulfadoxine-pyrimethamine in Africa. 
Chlorproguanil-dapsone-artesunate (CDA) is developed based on the ACTs to slow down the 
spread of drug resistance. The addition of artesunate causes rapid in vivo parasite clearance, 
thus reduce the parasite biomass sufficiently to allow the antifolate to clear away the remainder 
and delay the emergence of resistance to the combination. Clinical trials of CDA entered Phase 
III in 2005.  
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1.2.4.2 Fosmidomycin-clindamycin 
Fosmidomycin, which can clinically cure P. falciparum infection, exerts its anti-malarial 
activity by the inhibition of 1-deoxy-D-xylulose 5-phosphate reductoisomerase. This enzyme, 
which is absent in humans, is essential for the biosynthesis of isoprenoid in malarial parasites. 
The parasites were arrested at the late schizont stage when they were exposed in vitro to 
fosmidomycin for a full replication cycle (Lell et al., 2003). The combination of 
fosmidomycin-clindamycin showed a synergistic effect in the treatment of malaria. Rapid 
parasite clearance and 100% cure rates were achieved together in a clinical study. (Borrmann et 
al., 2004). 
1.2.4.3 Pyronaridine-artesunate (PANDA) 
Pyronaridine, a member of Mannich-base class schizontocides, has been used in clinical 
malaria therapy nearly 20 years in China. The development project of PANDA was supported 
by MMV for the treatment of acute uncomplicated malaria. The work on Phase I trial was 
completed in 2004.  Then  the project went into Phase II trial in 2005 and the work on 
Phase-III trial started in 2006. 
 
There are still many other combination regimens, which have been clinically used or trialed. 
However, the data does not encourage the use of those combinations on grounds of poor 
effectiveness, serious side effects, emergence of cross-resistance to those combinations before 
their use or expensive prices. They mainly include: sulfadoxine-pyrimethamine-chloroquine 
(poor effectiveness), sulfadoxine-pyrimethamine-mefloquine (poor synergistically efficacy, 
pharmacokinetic properties not match well, high price), sulfadoxine-pyrimethamine-
amodiaquine (serious side effects), sulfadoxine-pyrimethamine-quinine (poor synergistically 
efficacy), chlorproguanil-dapsone (Cross resistance emergenced before the use, serious side 
effects), quinine-tetracycline (serious side effects), quinine-clindamycin (serious side effects), 
Artesunate-sulfadoxine-pyrimethamine (poor effectiveness). 
1.3 The reason for the widespread of malaria 
1.3.1 No effective vaccine available against malaria 
Vaccine is an effective way to control infectious diseases. Remarkable examples are the 
eradication of smallpox, the virtual eradication of polio, and the striking reduction in the 
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prevalence of measles in the western hemisphere (Mahanty et al., 2003). As reported, there are 
special antibodies against malaria in the Sera from humans living in hyperendemic regions, 
which can prevent red cell invasion by targeting antigens on merozoites (Mahanty et al., 2003). 
Antibodies in purified immunoglobulins, which are passive transfered from ‘naturally immune’ 
individuals into partially immune children, were found to produce rapid clearance of parasites 
in recipient children even when the antibodies did not block growth in vitro (Mahanty et al., 
2003). Protective immunity could be inducted by defined antigens in animal models. Those 
researched indicated that it’s possible to develop a safe and efficacious malaria vaccines, which 
has attracted so much attention around the world for many years. However, even now, there is 
still no effective vaccine available against malaria, which is one of the most important reasons 
for the widespread of malaria. There are so many scientific and technical challenges for 
malaria vaccine development. Firstly, the Plasmodium is a highly complex parasite. Its genome 
encodes an estimated 5,600 proteins in the whole multi-stage life cycle. The parasite expresses 
a different repertoire of antigens in different stages, and multiple antigens exhibit remarkable 
polymorphisms. Both stage-specific expression and polymorphisms of antigen genes deployed 
in vaccine may profoundly influence the human immunity against malaria. This leads to the 
main hindrance to malaria vaccine development. Even now, no ideal target antigen is 
established, which showed a stable property among different stages and strains. Secondly, the 
antigens of malaria parasites inside RBC exposure to antibody occur only between release from 
one RBC and invasion of another. This provides a short window of opportunity for antibodies 
to bind and neutralize merozoites. Therefore, considerable effort is being devoted to the testing 
and development of new adjuvants for asexual blood stage antigens to enhance the delivery of 
antigen to immune system and get high antibody level. (Guinovart and Alonso, 2007; Mahanty 
et al., 2003). Thirdly, in humans, sera from immune individuals have high titers of antibodies 
against erythrocyte membrane protein 1 (PfEMP1) in addition to other surface and internal 
merozoite antigens, so investigators have speculated that PfEMP1 is a target for antibody-
mediated immunity (Mahanty et al., 2003). However, PfEMP1 is encoded by a large and 
diverse var gene family, which plays a key role in clonal antigenic variation. Immune pressure 
results in quick variation of PfEMP1. 
1.3.2 Drug resistance 
An important reason for continued innovation on anti-infectious drugs is the development of 
drug resistance. As a serious infectious disease, malaria is also challenging the effective 
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clinical therapy by the emergence of drug resistance. Studies on malaria drug resistance 
indicated that parasite clones resistant to some traditional anti-malarial agents acquire 
resistance to new ones at a high frequency (accelerated resistance to multiple drugs, ARMD). 
Drug resistance causes the incidence of malaria infection continues to increase at a significant 
rate. There are multiple factors that contribute to malarial-drug resistance, both from parasites 
and anti-malarial drugs. 
1.3.2.1 Parasite originated drug resistance elements: 
transporter and enzyme 
The genetic events in malaria parasites responsible for drug resistance are spontaneous and rare. 
Those events must not impact the viability of parasite. The drug resistance related genetic 
events include gene mutation and increase of gene copy number. The genes involved in the 
events mainly are responsible for the encoding of drug target or drug transporter. In some cases, 
a single genetic event may be sufficient to create drug resistance. 
1.3.2.1.1 Drug resistance related Plasmodium 
transporters 
There are two digestive vacuole membrane localized transporters mainly contribute to the drug 
resistance of P. falciparum parasite, chloroquine resistance transporter (PfCRT) and 
Pglycoprotein homologue 1 (Pgh1). The mutation of the two genes could confer resistance to 
many anti-malarial drugs presently used, such as chloroquine, mefloquine, quinine and 
halofantrine. The study on isolates from endemic areas of falciparum malaria showed that there 
is a typically positive correlation between mutations in either or both the two transporter genes 
and in vitro drug resistance. Several other transporters may also be related to drug resistance. 
Theoretical analysis has indicated that as many as nine putative transporter genes (including 
pfmdr1 and pfcrt ) showed significant associations with decreased CQ sensitivity, with linkage 
disequilibria suggesting there may be multiple interactions between these genes (Mu et al ., 
2003). 
1.3.2.1.1.1 PfCRT 
The pfcrt gene is located on chromosome 7 and encodes a 424 amino acid (48.6 kDa) protein. 
The PfCRT protein contains ten predicted transmembrane domains and is located on the 
membrane of the digestive vacuole, where the weak base chloroquine concentrates in its 
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diprotonated form and binds with hematin (a dimeric form of oxidized heme). PfCRT is a 
member of the drug-metabolite transporter superfamily. It was identified as a candidate gene 
for CQR by the analysis of a genetic cross between a chloroquine-resistant clone (Dd2, 
Indochina) and a chloroquine-sensitive clone (HB3, Honduras) (Wellems et al ., 1990). The 
specific polymorphisms in pfcrt are tightly correlated with chloroquine resistance. Transfection 
studies have shown that pfcrt mutations confer verapamil reversible chloroquine resistance in 
vitro and reveal their important role in resistance to quinine. The K76T mutation is crucial for 
chloroquine resistance. The other mutations may serve to compensate for a loss of endogenous 
function associated with the K76T mutation (Valderramos and Fidock, 2006).  
1.3.2.1.1.2 PfMDR1 
The protein Pgh1 localizes to the digestive vacuole membrane of P. falciparum. It is an analog 
to the P-glycoprotein (P-gp) over expressed in cancer cells. P-gp functions as pumps expelling 
cytotoxic drugs (ATP-binding cassette transporters) in drug resistant tumor cells. As reported, 
Pgh1 overexpression is associated with increased CQ susceptibility in strain-dependent 
manner. The mutations in Pgh1 is thought to be responsible for conferring resistance to anti-
malarials like mefloquine, quinine, halofantrine, chloroquine and artemisinins, which can cause 
impaired drug uptake by the parasite vacuole.  
1.3.2.1.1.3 Plasmodium falciparum CG2 
PfCG2, whose gene closely linked to the chloroquine resistance locus in chromosome 7, is a 
putative drug resistance related protein. PfCG2 is a peripheral membrane protein and is 
exposed to the erythrocyte cytosol at the outer face of the PVM. There is no significant 
evidence that PfCG2 involve in chloroquine resistance directly. However, the polymorphisms 
of pfcg2 are associated with chloroquine resistance.  
There are still some other putative transporter genes, located on different chromosomes, were 
associated with chloroquine and quinine resistance. (Valderramos and Fidock, 2006) 
1.3.2.1.2 Drug resistance related enzymes 
There several enzymes are related with the drug resistance of malaria. The mutation, single 
nucleotide polymorphisms or over expression could confer drug resistance to malarial 
parasites. 
1.3.2.1.2.1 Plasmodium falciparum dihydrofolate reductase (PfDHFR) 
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PfDHFR is the target of anti-malarial drugs proguanil (cycloguanil) and pyrimethamine. Single 
point mutation in pfdhfr is sufficient to create resistance and there are multiple foci showing 
high mutation frequency, explaining the rapid emergence of drug resistance. The S108N 
substitution is the principal mutation associated with resistance to pyrimethamine or 
cycloguanil in Africa and in South-east Asia. Substitution S108T is also found in South 
America. The most frequent additive mutations are N51I and C59R. The mean IC50-value of 
cycloguanil increases with the number of mutations. Higher level pyrimethamine resistance is 
associated with multiple mutations at the target site. However, multiple mutations diminish the 
efficacy of the enzyme on dihydrofolate and thus suggest that additional mutations are 
unfavourable to the parasites in the absence of drug pressure. 
1.3.2.1.2.2 Plasmodium falciparum dihydropteroate synthase (PfDHPS) 
PfDHPS is a key enzyme in the folate pathway of Plasmodium falciparum parasite. 
Sulfadoxine exerts its anti malaria action by the inhibition to this enzyme. The resistance to 
sulfadoxine is developed by mutations in PfDHPS. The crucial mutations lie at positions 436, 
437, 540, 581 and 613. 
1.3.2.1.2.3 Plasmodium falciparum ATP6 (PfATP6) 
Artemisinin specifically inhibit PfATP6, a SERCA-type ATPase of Plasmodium falciparum. 
Now PfATP6 is a candidate gene that has been associated with parasite response to artemisinin. 
As reported, a single amino acid in transmembrane segment 3 of SERCAs can determine 
susceptibility to artemisinin. The mutation in Leu263 in PfATP6 is crucial for the interaction 
between PfATP6 and artemisinin (Uhlemann et al., 2005). However, the association of 
mutations in PfATP6 with artemisinin resistance requires further clinical confirmation. 
 
Cross resistance: Multi-drug resistance for malaria refers to one parasite strain resists to several 
anti-malarial drugs with diverse structures, which can be simultaneous or cross-resistance. 
Multi-drug resistance is caused by the large-scale and simultaneous use of several anti-
malarials, which causes strong selective pressure. The parasites, with a high level of 
chloroquine resistance, are generally resistant to amodiaquine as well. The same is probably 
true for mefloquine and halofantrine. The cross-resistance between anti-malarials with diverse 
structures is a phenomenon linked to the common or shared aspects of their modes of action 
and probably of their resistance mechanisms, such as the cross-resistance between cycloguanil 
and pyrimethamine in Africa. Both cycloguanil and pyrimethamine exert their anti malaria 
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action by the inhibition against the same target, PfDHFR. The resistance to the two drugs is 
also conferred by the same mutations in PfDHFR. So the parasite strain, which is resistant to 
pyrimethamine, also be cross-resistant to cycloguanil, and vice versa. So it seems essential to 
combine the anti-malarial drugs without cross resistance tendency for treatment and for 
prophylaxis in order to limit the extension of resistant genotypes. 
1.3.2.2 Drug originated drug resistance elements 
Some properties of anti-malarial drugs are closely related to the emergence of drug resistance, 
which are crucial for the success of anti-malarial drug development. 
1.3.2.2.1 In vivo elimination half-life 
The response of malaria to treatment is determined by blood concentrations of anti-malarial 
drugs. Most of the drugs are absorbed more quickly than they are eliminated, which gives rise 
to the characteristic concentration-time profile: a maximum plasma concentration, achieved 
within a few hours of drug administration, followed by an exponential decline at a rate 
governed by the specific elimination rate constant. The residual drug concentration in the blood 
of the host will be sufficient to prevent reinfection until its concentration falls below the 
minimum parasiticidal concentration for a particular parasite genotype. Elimination half life is 
a very important pharmacokinetic parameter for all drugs, and refers to the time it takes for a 
drug to lose half of its pharmacological activity. Anti-malarial drugs with a long elimination 
half-life have two therapeutic advantages. Firstly, this kind of drugs can provide long-term 
protection against reinfection, such as pyrimethamine-sulphadoxine. Prolonged anti-malarial 
drug activity in vivo is an advantage to the patient who is recovering from malaria in an area of 
moderate or high transmission, because further disease episodes are prevented. Secondly, long 
half-life drugs require a fewer administrations, which reduces the risk of underdosage and 
some of the problems of compliance. However, a slow eliminated drug would persist in the 
patient for a very long time at low concentration, which means the residual drug constitutes a 
potent selective force for the emergence of drug resistance. For the development of 
pyrimethamine-sulphadoxine resistance, there is a very important model consisting of two 
separated phases. In phase A, intermediate levels of susceptibility parasite strain is spreading 
and replacing the original sensitive forms while drug resistant strain remains at a low level. 
Phase B starts once parasites are selected that can escape from drug action. Drug treatment is 
clinically successful during phase A, and health workers may be unaware of the substantial 
changes in parasite population genetic structure that predicate the onset of phase B. The very 
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rapid elimination of artemisinin, its derivatives and their active metabolites means that even 
fully susceptible parasites are affected by residual drug for times only marginally greater than 
the period of treatment. The drug effect is either maximal or zero. Artemisinin-based 
combination therapies have been widely used as the first line anti malaria treatments around for 
a decade. However, even now, widespread clinical artemisinin still not emerged. So drug in 
vivo elimination half-life is a critical factor for the development of drug resistance. 
1.3.2.2.2 The gene stability of drug target 
The gene stability of a drug target is closely related to the development of resistance to this 
drug. If the gene of an anti-malarial drug target showed a high frequency of pre-existing 
mutations, this drug would show a poor property against drug resistance selection as it is very 
easy for the parasite to develop resistance through mutation in a unstable target gene, such as 
pfdhfr.  
1.4 The targets used for the development of novel anti-
malarial drugs 
With the emergence of widespread drug resistance, novel anti-malarial drug development is the 
best way to override this problem. The novel anti-malarial drug will interact with a new target 
and exert their action by a different mechanism comparing with the presently used anti-
malarial drugs. Novel drug targets identification is crucial for the development of new anti-
malarial drugs. 
1.4.1 The drug targets of Plasmodium Falciparum in 
biochemical pathways 
Several parasite specific and essential biochemical pathways have been exploited for novel 
drug target identification. The Plasmodium Falciparum parasite should be killed selectively by 
the block to those pathways. With the development of in silico target screen among metabolic 
enzymes, more and more metabolic enzymes are proposed to be novel drug targets.  
1.4.1.1 The Plasmodium Falciparum specific biochemical 
pathways in the apicoplast  
The apicoplast in malaria parasite contains a range of metabolic pathways and housekeeping 
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processes, which are essential to the parasites and differ radically to those of the human host. 
Thus, those pathways are thought to be potential anti malaria drug targets, such as fatty acid, 
isoprenoid and heme synthesis. Presently, the most efficous anti-malarials targeting apicoplast 
are the antibiotics, such as clindamycin, tetracycline and azithromycin. Fatty acid synthesis is a 
major function of the apicoplast, which is crucial for the synthesis of cell and organellar 
membranes. There is an inherent difference between the fatty acid biosynthesis pathways of the 
parasite (type II) and the human host (type I), thus making them a promising target for the 
development of anti-malarials. Another promising drug target pathway is isoprenoid 
biosynthesis, which is essential in blood-stage. The significant evidence is the excellent 
activity of fosmidomycin, an inhibitor of the isoprenoid enzyme 1-deoxy-D-xylulose 5-
phosphate (DOXP) reductase. Some of vitamin biosynthesis pathways are also thought as 
novel targets for anti malaria drugs development, which occurs in P. falciparum but is absent 
in humans, such as the pyridoxal phosphate pathway and the biosynthesis pathway of 
coenzyme from the precursor pantothenate (vitamin B5).  
1.4.1.2 The Plasmodium Falciparum specific metabolic 
pathways in the mitochondrial  
Electron transport and protein synthesis are the major functions of mitochondria in 
Plasmodium Falciparum, which are also potential targets for anti-malarial chemotherapy. 
Plasmodium mitochondria use a different homolog of CoQ comparing their mammalian host, 
which offers a unique chemotherapeutic target for anti-malarial drug development. Atovaquone 
is an excellent anti-malarial drug, which was developed based on this target (complex III). It 
exerts its anti-malarial action by inhibiting electron transport and collapsing mitochondrial 
membrane potential, which is required for a number of parasite biochemical processes. 
Another potential drug target in Plasmodium Falciparum mitochondrial is Dihydroorotate 
dehydrogenase (DHODH). Plasmodium in humans can capture and use the host’s purines but 
not their pyrimidines, which means the de novo biosynthesis pathway is essential for the 
parasite. DHODH is a key flavin mononucleotide-dependent mitochondrial enzyme, which 
utilizes coenzyme Q as the final electron acceptor. As reported, several potent inhibitors of 
PfDHODH have been developed, which display IC50-values in the range 20-600 nM. Those 
compounds showed a 200-20 000-fold selectivity for the malarial over the human enzyme. 
Another drug target in mitochondrial is the quinol oxidation site (Qo) of the parasite 
mitochondrion bc1 complex, whose inhibitors can cause collapse of the mitochondrion 
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membrane potential and cell death. The inhibitors display a selectivity against the parasite 
enzyme that is 5000-fold higher than for human liver bc1. 
1.4.1.3 Choline biosynthesis pathway  
Intra-erythrocytic malaria parasites have to synthesize an abundance of phospholipids, which 
increases by as much as 500% in infected erythrocytes, for the development of the 
parasitophorous vacuole, cytosol and multiple subcellular compartments. At the same time, a 
large amount of phospholipids are used for the growth and divide of malaria parasites. The 
major of phospholipids in the membranes of plasmodial is phosphatidylcholine (PC), about 
45% of the total. Thus de novo phosphatidylcholine biosynthesis pathway is characterized as 
an excellent target for anti-malarial drug development, which is absent from mature human 
host erythrocytes. Choline transport is a rate-limiting step in this pathway. Choline analogs 
were developed based on the idea to inhibit choline transport. At the same time, choline 
analogs also could exert an effect on parasite phospholipid biosynthesis. As reported, choline 
analogs showed an IC50-value against P. falciparum parasites in asexual blood stages at single-
digit nanomolar concentrations. The in vivo test in rodents and non-human primates infected at 
high parasitemias showed that choline analogs exhibit a fully curative anti-malarial activity 
with short-course treatments. The chemical structure and modes of action are distinct from 
current anti-malarial agents, which could help delay the development of resistance. Now, this 
exciting new class of compounds have entered clinical trial (Schlitzer, 2008). 
1.4.1.4 Plasmodium Falciparum special proteases 
Malarial proteases play crucial roles in the parasite life cycle, which makes them potential anti-
malarial targets. They act as a key factor not only for the degradation of a myriad of 
hemoglobin, but also in the invasion and rupture of erythrocytes (McKerrow et al., 1993; 
Rosenthal, 2002). Hemoglobin (Hb) digestion is apparently mediated by many food vacuole 
aspartic proteases, cysteine proteases, metalloprotease and dipeptidyl aminopeptidase 1 
(DPAP1), by which the parasite captures the nutrient for its own protein synthesis (Sahu et al., 
2008). So those enzymes have long been defined as potential drug targets. As reported, 
inhibitors of falcipains 2 and 3 could prevent in vitro P. falciparum growth at low nanomolar 
concentrations. In vivo test in a new immunocompromised mouse showed that these inhibitors 
can cure P. falciparum infections propagated in human RBCs. However, the research on 
plasmepsin enzymes showed that parasites can survive, albeit with reduced growth rate, 
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without all four plasmepsins of the DV (Fidock et al., 2008). Cysteine protease inhibitor E-64 
could inhibit schizont rupture in P. falciparum and inhibitors of serine/cysteine proteases could 
inhibit merozoite invasion by three Plasmodium species significantly (Francis et al., 1997; 
Wang and Wu, 2004). So proteases would be promising targets for clinical therapeutics. 
1.4.1.5 Plasmodium Falciparum Carbonic Anhydrase (CA) 
inhibitors 
P. falciparum carbonic anhydrase plays a crucial role in the interconversion of carbon dioxide 
and bicarbonate at neutral pH and biosynthesis of pyrimidines, which is thought as a potential 
anti-malarial drug target. As reported, the inhibitor of P. falciparum Carbonic Anhydrase 
(PfCA) showed eccellent anti-malarial activity, with the IC50-value at the range of micro molar 
(A.A. Joshi 2006). 
1.4.1.6 Targeting the shikimate pathway 
Aromatic amino acids are essential in the diet of malaria parasite, which are synthesized by the 
shikimate pathway. However, this pathway is not present in human host. This pathway offers 
some potential anti-malarial drug targets. The enzymes in the shikimate pathway are localized 
in the cytosol of P. falciparum parasite. As reported, the analogs of shikimate and inhibitors of 
the enzymes in this pathway are able to inhibit P. falciparum growth.  
1.4.1.7 Microtubule inhibitors 
Microtubular systems are the principal components of mitotic spindles, which are essential for 
cell division and play a major role in cell motility. They contribute to the maintenance of cell 
shape and integrity and the organization of subcellular compartments. They also act as tracks 
for intracellular transport of vesicles and organelles. Now, the microtubular systems of malarial 
are thought as potential drug targets. Several inhibitors of tubulins, the principal proteins of 
microtubules, showed potential anti-malarial activity. However, the selectivity of those 
inhibitors need to be improved. 
1.4.1.8 Targeting the redox system 
Oxidative stress is caused by an imbalance between the production of reactive oxygen and a 
biological system's ability to clear the reactive intermediates or easily repair the resulting 
damage. It can cause toxic effects and damage all components of the cell, including proteins, 
Introduction 
 31
lipids, and DNA, to which Plasmodia is very sensitive. In intra-erythrocytic-stage malaria, 
parasites encounter reactive oxygen species (ROS) from either themselves or the host. Malaria 
parasites have their own biological system to prevent oxidative stress, including a series of 
antioxidant enzymes. The key enzymes of P. falciparum involved in redox metabolism are 
glutathione reductase, GPx, thioredoxin reductase, and thioredoxin peroxiredoxin. The parasite 
thioredoxin reductase differs from the host enzyme, which is thought as potential drug target. 
The inhibitors of thioredoxin reductase showed in vitro anti-malarial activity. Another potential 
target in this pathway is Plasmodial GST, which acts as a ligand for parasitotoxic hemin and is 
highly abundant in the parasite. The crystal structure of P. falciparum GST differs considerably 
from the human enzyme. So the specific inhibitors of GST should have promising future for 
development. 
1.4.1.9 Targeting the methionine cycle, methylation, and 
polyamines 
The methionine cycle in parasites has recently received attention as it is the essential 
biochemical pathway to provide substrates for methylation of DNA, RNA, proteins, 
phospholipids and for the synthesis of polyamines, which means the methionine cycle is 
involved in many key processes in the life cycle of parasite. Some enzymes and metabolites in 
this pathway are unique to parasites, which would offer potential targets for malaria 
chemotherapy. Polyamines play a crucial role in many key processes such as cell growth, 
differentiation, and macromolecular synthesis. Thus, the enzymes in the polyamine 
biosynthesis pathway were thought as potential targets for anti-malarial drugs development.  
1.4.1.10 Targeting nucleic acid metabolism 
Nucleic acid metabolism pathways are essential for the growth of malaria parasites. As those 
pathways differ between P. falciparum and the human host, they are thought as promising drug 
targets. Plasmodium in humans can capture and use the host’s purines but not their pyrimidines. 
Plasmodia synthesize pyrimidines by de novo biosynthetic pathways. The human host cells 
synthesize purines de novo and either salvage or synthesize pyrimidine by a de novo pathway. 
Hypoxanthine-guanine phosphoribosyltransferase (PfHGPRT) and purine nucleotide 
phosphorylase (PfPNP), two key enzymes of purine synthesis pathway in P. falciparum 
parasites, are thought as potential drug targets. As reported, inhibitor of PfPNP showed anti-
malarial activity. Pyrimidine biosynthesis also presents an attractive drug target in malaria 
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parasites because of the absence of a pyrimidine salvage pathway. The key enzymes in this 
pathway include carbamoyl phosphate synthase, aspartate transcarbamylase, dihydroorotase, 
dihydroorotate dehydrogenase (PfDHODH), orotate phosphoribosyl transferase and orotidine 
5-phosphate decarboxylase. 
1.4.1.11 Targeting folate metabolism 
Folate metabolism pathway is essential for the synthesis of nucleotides required for DNA 
replication and the synthesis of the amino acids glycine and methionine. It also plays a very 
important role in the metabolism of histidine, glutamic acid and serine and protein synthesis in 
mitochondria through formylation of methionine. So folate metabolism pathway is one of the 
most common pathways that have proved to be a valuable target for decades. There are two 
classes of drugs targeting this pathway: inhibitors of dihydropteroate synthase (DHPS) (known 
as class I antifolates) and inhibitors of dihydrofolate reductase (DHFR) (the class II antifolates). 
Anti-malarials such as proguanil, chlorproguanil, clociquanil and pyrimethamine exert their 
activities by inhibiting dihydrofolate reductase (DHFR). Dapsone is a sulfa drug, which kills 
malarial parasites by inhibitting dihydropteroate synthase (DHPS) (Triglia et al., 1997). The 
combination of the two classes of drugs is synergistic in clinical, hence their use in 
combination in the treatment of malaria. Dapsone was combined with pyrimethamine as 
Maloprim. Lapdap is a combination of chlorproguanil and dapsone.  
1.4.1.12 Glycolysis 
Malaria parasites are microaerophic homolactate fermenters and rely on glycolysis for ATP 
production. So the glycolytic pathway is a vital pathway for malaria parasites, which may be a 
novel target. There are 11 enzymes to convert glucose to lactic acid in glycolytic pathway, 
among which three enzymes are considered to be rate-limiting: hexokinase, 
phosphofructokinase and pyruvate kinase. The three enzymes may be novel targets for the 
development of anti-malarials. P.falciparum Lactate dehydrogenase (PfLDH) is a key enzyme 
in the glycolytic pathway of P. falciparum and has several unique amino acids, related to other 
LDHs, at the active site, making it an attractive target for anti-malarial agents. As reported, one 
class of PfLDH inhibitors have recently been shown to have anti-malarial activity both in vitro 
and in vivo (Sahu et al., 2008).  
Introduction 
 33
1.4.1.13 Targeting Hematin or the Hemozoin Crystal 
Heme, hematin or hemozoin are believed to be the targets of many anti-malarials, such as 
chloroquine, quine, mefloquine and artemisinin. Heme has been implicated as the target of 
endoperoxide anti-malarials, such as artemesinin, which have been proposed to form radical 
adducts with heme that act against the parasite. Hematin is thought as the target of chloroquine 
and other quinoline anti-malarials. As reported, those drugs act by preventing the 
detoxification of hematin, which are normally converted to hemozoin or malaria pigment. The 
accumulation of hematin causes toxicity to parasites. Chloroquine has variously been proposed 
to inhibit hemozoin formation via direct interaction with hematin. The research indicated that 
this pathway is an important target for novel anti-malarial drugs development. 
 
There are still many other metabolic enzymes, which are viable targets for novel anti-malarial 
drugs development, such as P. falciparum Peptide Deformylase (PfPDF), Erythrocyte G 
Protein, helicases and Farnesyl transferase. 
1.4.2 Other drug targets of Plasmodium Falciparum 
With the exception of the metabolic enzymes, there are still many other types of drug targets in 
malaria parasites, including transporters and permeability pathways. 
1.4.2.1 New permeability pathways (NPPs)  
Molecular traffic across the host erythrocyte membrane undergoes dramatic changes with 
respect to intensity and the nature of permeating solutes. The induced permeability pathways 
are known as new permeability pathways (NPPs). They occurs 12-16 hrs post erythrocyte 
invasion by merozoite (Becker and Kirk, 2004). NPPs are involved in the increasing 
permeability of host erythrocyte membranes to a wide range of low molecular weight solutes. 
They are thought to provide the major entry of some essential nutrients (pantothenate) required 
by the parasites and mediate the efflux from the infected cell of various metabolic wastes, such 
as lactic acid and amino acids (Saliba et al., 1998). The pathways are broadly anion selective, 
but with a significant permeability to both organic and inorganic cations (Becker and Kirk, 
2004). The properties of the parasite-induced transport systems are significantly different from 
those in normal human cells. Therefore, these transport systems are proposed to be targets for 
anti-malarial chemotherapy. The drugs targeting on this pathway will exert their activities by 
inhibiting the transport and hence depriving the parasite of nutrients essential for its 
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development or by selectively entering the parasite through these induced transporter routes 
and hence cannot enter normal mammalian cells. NPPs are inhibited by a range of classical 
anion transport blockers and various derivatives, some of which are effective at nanomolar 
concentrations. There are many new anti-malarial candidate compounds targeting NPPs. The 
most potent NPP inhibitors are based on furosemide and 5-nitro-2-(3-phenylpropylamino) 
benzoic acid (NPPB), amongst which the most effective one exhibited an IC50-value around 
100 nM.  
1.4.2.2 Parasite transporters  
There are some essential transporters in malaria parasites involved in nutrient acquisition from 
the host, which are also under investigation as candidate targets. As reported, this kind of 
parasite-specific transporters include PfFBT1, PfFBT2, PfHT and the P. falciparum V-type H+-
ATPase. The inhibition to these transporters will block some necessary metabolism pathways 
of parasites and cause the death of them. 
1.5 Aim of this study 
The aim of this study is to identify novel anti-malarial drug candidates, with distinct chemical 
structures from current anti-malarial agents. The candidate compounds would showed excellent 
activities against P. falciparum blood stage and exert their anti-malarial action by a novel 
mechanism, which could be used as efficacious anti-malarial drugs in the future to override the 
widespread drug resistance.  
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2 Material and method 
2.1 Materials 
2.1.1 Equipment 
Analytical scales  Sartorius, Göttingen  
Autoclave  Tuttnauer Systec 2540, Wettenberg  
automated 12-channel pipette aid Eppendorf, Germany 
Cell harvester Packard, USA 
Centrifuges:   
J2-MC  Beckman, Krefeld  
RC5BPlus  Sorvall, Langenselbold  
Megafuge 2.0R  Heraeus Instruments, Hanau  
Megafuge 1.0R  Heraeus Instruments, Hanau  
Biofuge fresco  Heraeus Instruments, Hanau  
Biofuge pico  Heraeus Instruments, Hanau  
CCD Camera  Princeton Instruments, USA  
Computer-software:   
Adobe Photoshop® 5.0  Adobe Systems Inc, USA  
Chromas  Technelysium.com.au/chromas  
ClustalW  http://www.ebi.ac.uk/Tools/clustalw/  
EndNote 8.0.2  ISI Research Soft, CA, USA  
MS Powerpoint  Microsoft Corporation, CA USA  
MS Word 98  Microsoft Corporation, CA USA  
Sigmaplot 9.0 Systat Software, Inc. USA 
Internet Explorer  Microsoft Communications Corp., USA  
Freezer -80ºC, UF85-300S Heraeus GmbH, Hanau  
Freezers -20ºC Liebherr, Biberach  
Icemachine AF 30 Scotsman, Milano, Italy  
Incubator (P. falciparum) Heraeus Instruments  
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Liquid nitrogen tank Air Liquide, Ludwigshafen  
Magnetic stirrer Heidolph, Schwabach  
Microscopes: Zeiss, Jena  
Microwave oven AEG, Nürnberg  
pH-meter pH 537 WTW, Weilheim  
Microtiter plate scintillation counter Packard, USA 
Printer hp LaserJet 1300 Hewlett Packard, Heidelberg  
Quartz cuvettes Hellma, Müllheim  
Spectrophotometer UVIKON 923 Kontron Instruments,  
Sterile work bench Herasafe Heraeus Instruments, Hanau  
Stop watch Roth, Karlsruhe  
UV-lamp Typ N-6 L Benda Laborgeräte und Ultraviolettstrahler  
UV-table UV-Transilluminator Gibco BRL, Karlsruhe  
Vortex Genie 2 Roth, Karlsruhe  
Water bath Julabo 7A Julabo, Seelbach  
2.1.2 Disposables 
Aluminium foil  Roth, Karlsruhe  
Centrifugation tubes, Polypropylen-12/75  Greiner Bio-one, Frickenhausen  
Centrifugation tubes, Polystyren-6, 0/38 mm  Greiner Bio-one, Frickenhausen  
Clingfilm Saran  Dow Chemical Company, Schwalbach 
Coverslides  Roth, Karlsruhe  
Cryovials  Nalgene®, Wiesbaden  
Cuvettes  Sarstedt, Nümbrecht  
Electroporation cuvettes  Biorad, München  
Eppendorf tubes  Sarstedt, Nümbrecht  
Falcon tubes (15 ml; 50 ml)  Corning incorporation, Bodenheim  
Gloves  Hartmann, Heidenheim  
Immersion oil  Zeiss, Jena  
Object slides  Marienfeld, Lauda-Königshofen  
Parafilm  American International CanTM, USA 
Plastic pipettes  Corning incorporation, Bodenheim  
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Sterile filters (0,2 μm)  Corning incorporation, Bodenheim  
96-well sterile culture plates(sterile, F-botton with lid) Greiner bio-one 
Unifilter plate GF/C-96/50 Perkin Elmer LAS, The Netherlands 
2.1.3 Buffers, media and solutions 
10% Human serum  
0.2 μg/ml Gentamycin  
0.1 mM Hypoxanthine  
Cell culture media  
in RPMI 25 mM HEPES L-Glutamine (Gibco) 
28% Glycerol (v/v)  
3% D-Sorbitol  
0,65% NaCl in ddH2O  
Freezing Solution  
filter sterilize  
[3H]-hypoxantine 
10-30 Ci/mmol, 1mCi/ml 
Perkin Elmer 
Scintillation cocktail, Microscint Perkin Elmer 
5% (w/v) D-sorbitol in ddH2O  Sorbitol Solution  
filter sterilize  
Thawing solution I  12% NaCl autoclave  
Thawing solution II  1.6% NaCl autoclave  
0.9% NaCl / 0.2% glucose  Thawing solution III  
filter sterilize  
2.1.4 Chemicals 
The screened anti-malarial compounds were provided by 4SC. The structures of the 
compounds were checked by NMR, and the purity was analyzed by HPLC, which were more 
than 99%. The other chemicals used in this study are from the firms Merck, Sigma, Serva and 
Applichem and were ordered directly or through the Chemical facility of the Heidelberg 
Medical faculty.  
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2.1.5 Plasmodium falciparum strains 
Dd2 (the laboratory line Dd2 originated from Thailand), 3D7 (clone from NF54, which was 
isolated from a patient who lived near the airport in Amsterdam), D10 (originated from Papua 
New Guinea), K1 (originally isolated from a Thai patient), 7G8 (isolated from Brazil), FCR3 
(originated from the Gambia, West Africa), Thai19 (originated from Thailand). 
2.2 Method 
2.2.1 Cell culture 
2.2.1.1 In vitro culture of Plasmodium falciparum 
Erythrocytic forms of P. falciparum Strains (Dd2, 3D7, D10, FCR3, K1, 7G8, Thai19) were 
maintained in continuous in vitro culture as described previously (Trager and Jensen, 1976). 
The parasites were cultured in A+ human erythrocytes at a hematocrit of approximately 5% in 
Petri dishes of either 10 cm or 25 cm diameter containing 15 ml or 35 ml, respectively, of 
HEPES-buffered RPMI medium supplemented with 10% human serum type A+ ,20µg/ml of 
gentamicin and 100 µM of hypoxanthine. The parasite cultures were incubated in an 
atmosphere of 3% CO2, 5 % O2, 92 % N2, and 95% humidity at 37°C. Every two to three days, 
the parasitemia determined by Giemsa-stained blood smears and medium was exchanged. By 
the time the parasitemia had reached 5-10%, the culture was split in order to avoid parasite 
death due to high levels of toxic metabolites in the medium.  
2.2.1.2 Preparation of human serum and erythrocytes 
Human group/type A+ erythrocytes concentrate and A+ human serum were obtained from the 
blood bank of the German Red Cross, Heidelberg. The human serum was prepared as follows. 
It was aliquoted into 50 ml falcon tubes. In each falcon tube, 800 μl of sterile 1 M CaCl2 was 
added, and then incubated first at 37°C for 30 mins and overnight at 4°C. The next day the 
tubes were centrifuged at 4000 rpm for 30 mins to pellet the fibrin and incubated at 56°C for 
30 mins to inactivate the complements in serum. Thereafter the serum was kept at -20°C. The 
erythrocyte concentrate was aliquoted into 50 ml Falcon tubes. 10 ml RPMI medium was 
added and the tubes were centrifuged (2300 rpm, 4 min) and then kept for two to three weeks 
at 4°C.  
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2.2.1.3 Staining of P. falciparum with Giemsa 
To enable determination of parasitemia and parasite developmental stage, thin smears of the 
culture were made as follows: 50 μl of culture were spread evenly onto the surface of a clean 
microscope slide, air dried, fixed in 100% methanol for 30 sec, and again air dried. Fixed cells 
were stained for 5-10 min in a solution of 10% Giemsa, washed with water and allowed to dry.  
2.2.1.4 Determining parasitaemia 
The parasitemia is the percentage of P. falciparum infected erythrocytes. Giemsa-stained blood 
smears were examined on a light microscope under oil immersion using a 100x objective. The 
number of both infected and uninfected erythrocytes was counted in ten consecutive fields, 
with multiple infections assessed as single parasites. The parasitemia was then calculated 
according to the following formula:  
(Number of parasites / Number of erythrocytes) * 100= parasitemia (%).  
2.2.1.5 Parasite synchronization at Ring stage with sorbitol  
Sorbitol (5%) treatment at 37 °C causes osmotic lysis of late stage trophozoites (Lambros and 
Vanderberg, 1979). This selective lysis by osmotic shock is possible due to an induced 
transport pathway in the red cell membrane that is permeable to sorbitol. This transport 
pathway present in late stage trophozoites, while absent in ring stage parasites. Culture media 
was removed from the culture dish, and the blood resuspended in 10 ml of filter-sterilized, pre-
warmed 5% D-sorbitol solution and transferred to a Falcon tube. After a 10 min incubation at 
37°C the suspension was then centrifuged (1900 rpm, 2 min, RT). The pellet was washed with 
10 ml complete culture medium two times, before re-suspended in 15 ml of media and returned 
to the culture dish. For a tightly synchronized culture, this procedure was repeated for three 
times successively at the transition from schizonts to ring stage, which means only the first few 
rings survived. The age difference is confined to few hours. 
2.2.1.6 Freezing parasites 
A culture used for freezing should be at ring stage with a parasitemia higher than 5%. Infected 
erythrocytes were centrifuged at 1900 rpm for 2 min. The supernatant then removed, then the 
pellet re-suspended in equal volume of sterile freezing solution. The suspension was gently 
mixed, filled into a cryotube at a volume of about 1 ml and snap frozen in an ethanol/ dry ice 
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slurry for 15 min. The frozen parasites can stay for several months at -80°C or for longer 
storage in liquid nitrogen at -196 °C.  
2.2.1.7 Thawing parasites 
The cryotube was removed from the liquid nitrogen tank and thawed in a 37°C water bath for 2 
min before being transferred to a 15 ml Falcon tube. Add 200 μl of 12% NaCl to 1 ml of blood, 
and stand for 3 min at RT. Then a further 7 ml of 1.6% NaCl was then added at a rate of 4 to 6 
drops per minute. Then the suspension was centrifuged at 1900 rpm for 2 minutes. The 
supernatant was then removed. 7ml of 0.9% NaCl /0.2% glucose was added at a rate of 4 to 6 
drops per minute. The suspension was then centrifuged as before, the supernatant removed and 
the parasite pellet resuspended in 15 ml of complete parasite medium and transferred to a Petri 
dish. 0.5 ml of fresh blood was then added, and the dish transferred to the parasite incubator. 
The parasite culture was left in the incubator for two days before the medium would be 
changed and the parasitemia determined. All solutions were pre-warmed to 37°C before 
starting the thawing procedure.  
2.2.2 Compound screen 
2.2.2.1 Compound preparation for screening 
The anti-malarial compounds from 4SC were dissolved in DMSO at the concentration of 100 
mM. And, they were diluted to 100 µM by the medium before screening.  
2.2.2.2 [3H]-hypoxanthine incorporation inhibition based anti-
malarial compounds screening 
Drug activity in vitro was determined based on the inhibition of the incorporation of [3H]-
hypoxanthine into parasite nucleic acids according to the method of Desjardins et al. 
(Desjardins et al., 1979), at 2.5% final hematocrit and 0.5% parasitemia. The detail is as 
follows: 
A culture of highly synchronized rings are diluted in RPMI 1640 medium supplemented with 
10% human serum type A+ (supplemented 20 µg/ml of gentamicin and 3 µM of hypoxanthine) 
to yield a hematocrit of 2.5% and parasitemia of 0.25-0.5% . 
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The compound to be tested is dissolved in DMSO at the concentration of 100 mM and kept at -
20 °C. From this a working stock solution of 100 µM is prepared in the culture media 
described above. 
X 1 2 3 4 5 6 7 8 9 10 11 12 
A             
B             
C             
D             
E             
F             
G             
H             
Fig. 2.1: Layout of the microtiter plate 
• add 100 µl of culture medium (see above) to all wells. 
• add 50 µl the compound to be tested (from the 100 µM working solution) to wells B1-
 B2 (drug number 1), duplicative determinations 
• follow the same procedure for the other wells  
? 50 µl of 0.6 mM drug 2 to B3-B4 
? 50 µl of 0.6 mM drug 3 to B5-B6 
? 50 µl of 0.6 mM drug 4 to B7-B8 
? 50 µl of 0.6 mM drug 5 to B9-B10 
? 50 µl of 0.6 mM drug 6 to B11-B12 
• mix using the multi-channel-pipette. 
• take 50 µl from row B and transfer it to row C. 
• take 50 µl from row C and transfer it to row D. 
• follow the same procedure for rows E to H. 
• remove 50 µl from row H and discard it. This will result in 1:3 dilution steps. 
• add 100 µl of the Dd2 culture (2.5% hematocrite, 0.3-0.5% parasitemia ring stages) to 
each well. 
• Incubate for 48 hrs at 37°C in the gassed incubator. 
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• Add 50 µl of the [3H]- hypoxanthine-solution to each well:  
? Each well will receive 0.5 µCi [3H]-hypoxanthine. The 
hypoxanthine solution is prepared as follows: Take the appropriate 
amount of labeled [3H]-hypoxanthine, evaporate the solvent and then 
resuspend [3H]-hypoxanthine in the appropriate volume of culture 
medium at a final concentration of 0.5 µCi / 50 µl. 
• Incubate for 24 hrs more at 37°C in the gassed incubator 
• Harvest cell on glass-filter plates, using the cell harvester. 
• Dry glass-filter at 60 °C for 60 min. 
• Add 20 µl of scintillation cocktail and determine the incorporated radioactivity using 
the microtiter plate scintillation counter. 
• Save the data on a disk and transfer them to Sigma Plot for further analysis. 
• Subtract the amount of radioactivity associated with the uninfected erythrocyte control 
• Graph the percent growth as a function of the compound concentration. 
• Fit the data points using a Hill function. 
2.2.3 Parasitological evaluation of SC81458  
2.2.3.1 In vitro antiplasmodial assay 
The anti-malarial activity of SC81458 in vitro was determined as before. The activity of 
SC81458 comparing with chloroquine, quinine, mefloquine, halofantrine, quinidine, 
pyrimethamine, amodiaquin, artemisinin against Dd2, 3D7, D10, FCR3, 7G8, K1 and Thai19 
were determinated. 
2.2.3.2 Stage-specific susceptibility 
The stage-specific susceptibility of SC81458 against P. falciparum was evaluated according to 
the method of Henri J. Vial, Sharon Wein with some modifications (Vial et al., 2004). Briefly, 
Dd2 was highly synchronized by three successive sorbitol lysis treatments. SC81458 was 
added at various concentrations to synchronized parasites in culture at rings (2-4 hrs post 
invasion), trophozoites (24-26 hrs post invasion) and schizonts (35-37 hrs post invasion). 
Incubation was continued for 6 hrs, cells were washed twice and resuspended in fresh complete 
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medium. [3H]-Hypoxanthine was added at 54 hrs to monitor parasite viability. Reactions were 
stopped at 78 hrs and parasitemia was evaluated for each stage and expressed as a percentage 
of the control (without drug). 
2.2.3.3 Time course of Plasmodium falciparum growth inhibition 
The time course of Plasmodium falciparum growth inhibition of SC81458 against P. 
falciparum was evaluated according to the method of Henri J. Vial, Sharon Wein with some 
modifications (Vial et al., 2004). Briefly, Dd2 were highly synchronized by three successive 
sorbitol lysis. SC81458 was added at 100 nM, 500 nM, 1 µM, 5 µM, 10 µM to synchronized 
cultures at rings (2-4 hrs post invasion), trophozoites (24-26 hrs post invasion) and schizonts 
(35-37 hrs post invasion), respectively. After incubation for the times indicated, cells were 
washed twice and resuspended in fresh complete medium. [3H]-hypoxanthine was  added at 54 
hrs to monitor parasite viability. Reactions were stopped at 78 hrs, and parasitemia were 
expressed as a percentage of the control (without drug). 
2.2.3.4 Drug resistance induce property to Dd2 
Drug resistance inducibility of SC81458 to Dd2 was evaluated according to the method of 
Rathod, et al (Rathod et al., 1997). Briefly, Dd2 were challenged by SC81458 at the 
concentration of 100 nM with different beginning parasite number (108,107,106,105) for eight 
weeks. At the same time, 5-fluoroorotate (100 nM) was used as drug resistance positive 
control. A small portion of the culture material was smeared onto a slide per week and the slide 
was stained with Giemsa in order to observe the appearance of recovered parasites. 
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3 Results 
3.1 Cell based compounds screen and optimization 
Table 3.1 showed the IC50-values of different 
benzamidine derivatives against P. falciparum 
blood stages (Figure 3.1). All the 
sulfonamido-phenyl-ureido benzamidine 
compounds were designed and synthesized by 
4SC AG, Munich. IC50-values were 
determined, using a standard cell proliferation assay, in which P. falciparum blood stages 
(Dd2) were exposed to the drug for 72 hrs. The data obtained were analyzed and the half 
maximal inhibitory concentrations, IC50-values, determined. As table 3.1 indicated, the 
compounds displayed a broad range of IC50-values ranging from nano molar to micro molar. 
The replacement of simple aliphatic by aromatic groups showed a significant increase in 
activity (compare compound 13 with compounds 6-11). However, simple aniline derivatives 
were not active (see compound 12, 15, 16 and 24) and the methylene spacer of the benzyl 
moiety played a fundamental role for the high anti-P. falciparum activity (see compound 13, 
17-23 and 25). In general, 4’-substitution gave more active compounds when compared with 3’ 
substitutions (compare compound 13 with 14, 20 with 21; 22 with 23). Substitution of the 
phenyl ring with one or more fluoro atoms helped to increase the activity, and the tri-
substitution with fluoro atoms produced a very active compound (see compound 20). The best 
activity (IC50 = 10 nM) was obtained with compound 25, where a bulky para-sulfonamino 
group was introduced. The removal of the amidino group or its complete substitution with an 
amine, amide or ester group abolished the anti-P. falciparum activity. Sulfonamido 
substitutions on the east side of the diarylurea were preferred to simpler carbonyl-amino, 
amino-sulfonyl and amino-carbonyl groups. 
 
H
N
H
N
O S
H2N
NH
O
O
R
3'
4'  
Fig. 3.1: The structure of sulfonamido-
phenyl-ureido benzamidine compounds. 
R stands for side chains variation shown in 
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Table 3.1: Anti-P. falciparum activity of different sulfonamido-phenyl-ureido benzamidine 
derivatives.  
The chemical structure of the parental compound is shown in Fig 3.1. ND, not determined, which was 
caused by a poor solubility of the compound in the medium. 
 
Compound 
Sulfon 
position 
R- Activity vs Dd2 
   IC50 (nM) 
6 4’ -NH2 49900 
7 4’ -NH-CH3 4400 
8 4’ -NH-CH2-CH2-CH3 4750 
9 4’ -NH-CH2-CH2-OH 1100 
10 4’ 
H
N N
O  
ND 
11 3’ N OH
OH
 
> 5000 
12 4’ 
H
N
 
9000 
13 4’ HN  
450 
14 3’ HN  
> 5000 
15 4’ 
H
N
 
8200 
16 4’ 
H
N
 
17000 
17 4’ H
N
F
 
620 
18 4’ H
N
F
 
320 
19 4’ HN
F
F  
1110 
20 4’ HN
F
F
F
 
17 
Results 
 46
21 3’ HN
F
F
F
 
220 
22 4’ H
N
CF3
 
390 
23 3’ H
N
CF3
 
710 
24 4’ 
H
N
S NH2O
O
 
19000 
25 4’ 
N
H
S
O
O NH2  
10 
 
As Table 3.1 showed, these compounds vary in the position of the sulfon and the R 
substitutions. The results of the SAR study indicated that the novel class of anti-malarial 
compounds was diarylurea, with a benzamidine group on the west side of the diaryl urea and a 
sulfonamido-benzyl substitution on the east side. This class of compounds was further 
characterized, particularly with the determination of their physicochemical and ADMET 
properties to find the ideal candidate for development as potential anti-P. falciparum drug and 
provide necessary data for further SAR analysis. 
3.2 Anti-malarial mechanism: comparative study between 
sulfnamidomethylen and diarylsulfone compounds 
Sulfonamido-phenyl-ureido benzamidine compounds were further optimized for better anti-P. 
falciparum activity with the direction of SAR analysis. We analyzed two subclasses: the 
“sulfnamidomethylen” and the “diarylsulfone”. As the two classes of compounds came from 
the same lead compound, the structures of them were very similar. However, we were not sure 
that the two classes of novel anti-P. falciparum compounds exerted their action by the same 
mechanism. The SAR analysis for further optimization was based on the assumption that all 
the analyzed compounds exert their action by the same mechanism. So we compared the anti- 
P. falciparum mechanism between the two compound classes, which was crucial for further 
SAR analysis.  
The dose-response curves revealed important information, such as the shape and the steepness 
(Hill number). As Fig 3.2 shows, the dose-response curve of diarylsulfone compound showed a 
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biphasic property, while the dose-response curve of sulfnamidomethylen was single phasic and 
very steep. The dose-response curves of the two classes of compounds indicated that they exert 
their anti-P. falciparum action by different mechanisms. 
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Fig. 3.2: The dose-response curves of K20017701 and SC82686. 
K20017701 and SC82686 are representative example compounds of the diarylsulfone and 
sulfnamidomethylen subclasses, respectively.  
 
The data from the microscopic examination was consistent with the dose-response curve of 
diarylsulfone, which revealed that, at low drug concentrations, parasites were not killed but 
rather growth-arrested. Full killing only occurred at much higher concentration. We speculate 
that these compounds might interact with two targets: with high affinity against a target that 
would block parasite growth (observed at low concentrations) and with a lower affinity against 
a target that would kill the parasites (observed at high concentrations).  
To further compare the anti-P. falciparum mechanism of the two subclasses, a cross-resistance 
study between them was performed based on a sulfnamidomethylen resistant Dd2 strain. The 
sulfnamidomethylen resistant Dd2 strain, recovered from a long term exposure to a low 
concentration of SC81458, showed cross-resistance to active sulfnamidomethylen compounds 
(data not shown).  
As Fig. 3.3 indicates, there was no significant difference between the sensitivity of K20017701 
against SC81458 sensitive and resistant Dd2. However, the IC50-value of SC81458 to the 
resistant Dd2 strain is 30 folds of that to parental Dd2. So the two subclasses of compound 
most likely kill Dd2 parasites by different mechanisms. 
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Fig. 3.3: The dose-response curves of K20017701 and SC81458 to Dd2 (cycle) and Dd2 recovered 
from 50 nM SC81458 (Square). 
Dd2 cultures (108 infected erythrocytes/10ml/plate) were exposed to 50 nM of SC81458. Parasites were 
cultured by standard methods in the presence of 2% hematocrit with medium changes three times per 
week. In addition, cultures were split 1:2 with fresh erythrocytes once a week. Slides were prepared 
from the plate with each medium change and stained with Giemsa to test for the emergence of parasites. 
Dd2 parasite recovered 38 days post-challenge. The strain was transfered to drug free medium and 
assayed using the standard cell proliferation assay.  
 
The dose-response curve of diarylsulfone revealed a biphasic dose-response curve. As Figure 
3.4 indicated, similarly complex dose-response curves were observed when this compound was 
test against ring/trophorzoite and trophozoite stage parasites. The nature of the complex dose-
response curves was not investigated in this study. A possible interpretation might be that this 
class of compounds interacts with multiple parasite factors. No further optimization was 
conducted on this subclass of compounds. 
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Fig. 3.4: Action of diarylsulfone against ring / trophozoite and trophozoite stages of P. falciparum. 
Proliferation assay using ring-stage (A) parasites (5 hrs post invasion) that were exposed to 
diarylsulfone (K20017701) for 22 hrs before [3H]-hypoxanthine addition. Incubation with [3H]-
hypoxanthine for 3 hrs and the cells were subsequently analyzed for hypoxanthine incorporation. 
Proliferation assay using trophozoites (26 hrs post invasion) that were exposed to K20017701 for 6 hrs 
before [3H]-hypoxanthine addition. Incubation with [3H]-hypoxanthine was for 3 hrs and the cells were 
subsequently analyzed for hypoxanthine incorporation. 
 
3.3 The structure-activity relationship of SC81458 
SC81458 was obtained by further optimization of sulfnamidomethylen compounds, taking into 
consideration the in vitro anti-P. falciparum activity and the ADMET properties. 
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Fig. 3.5: The dose-response curve 
of SC81458 against P. falciparum.  
Fig. 3.6: The structure of SC81458 
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To further understand the structural determinants of SC81458, a structure-activity relationship 
study was performed by 4SC, which was based on the data of the IC50-determinations and 
ADMET evaluation of a series of compounds. All the compounds used in the SC81458 SAR 
study were designed and provided by 4SC. SAR analysis on SC81458 would provide crucial 
information for further optimization. As Fig 3.6 indicates, the structure of the compound was 
divided into three regions and each one of them was investigated, introducing tailored 
structural variations. Four different blocks of compounds were synthesized and analyzed: short 
fragments, variation to the sulfonamidomethylen group at the east-side, variations at the urea 
bridge and variations at the functionalized amidine group at the west-side. All compounds were 
tested using a standard cell proliferation assay (Desjardins et al., 1979). The results are shown 
in tables 3.2, 3.3, 3.4, 3.5, 3.6 and 3.7.  
Results 
 51
As table. 3.2 indicates, the presence of the amidino function on the west side was necessary for 
the anti-P. falciparum activity of SC81458, and no fragment starting from the east side showed 
any anti-P. falciparum activity even at a high concentration (16 µM). These data suggested that 
both east and west side of SC81458 are functionally important for the anti-plasmodium activity 
of this compound. A shorter fragment of SC81458, even with a smaller loss of molecular 
structure, did not exhibit good in vitro anti-P. falciparum activity.  
Table 3.2: The IC50-values of shorten side chains of starting from either the east or the west side 
against P. falciparum.  
 
N° Fragment Structure IC50 (µM) 
West 
1  > 16  
2  ND 
3  ND 
4  4.56 
5  2.17 
6  0.594 
east 
7  > 16  
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8  > 16  
9  > 16  
10  > 16  
11  > 16  
12  > 16  
ND, not determined, which was caused by poor solubility of the compound in the medium. 
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As table 3.3 indicates, the presence of a polar oxygen atom on the east-side of the molecule is 
detrimental to the activity (see compound 15, 16 and 17). Additionally, the dose-response 
curves of these compounds never showed the same steepness as that of the parent compound 
SC81458 (data not shown). 
 
Table 3.3: Activity of east side analogues of SC81458 vs P.falciparum . 
N° Structure (-R) IC50 
(µM) 
13  1.15 
14  0.597 
4  4.56 
5  2.17 
15  1.76 
16  6.25 
17  2.57 
6  0.594 
18  0.544 
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The sulfonamidomethylen linker of SC81458 is involved in the metabolic stability of the 
compound (4SC unpublished data). In an effort to improve the metabolic stability of SC81458, 
several structural analogues were synthesized with different tethering groups linking ring B 
and C. As table 3.4 indicates, none of the compounds reached the activity of the parent 
compound; even the most conservative replacements (see compounds 19, 20, 23). The 
fundamental role of the sulfone group is shown by compound 20 with an IC50-value higher 
than 2 µM. Reversal of the tether (long, short or carbonyl) produced compounds which were 
ca. 40-fold less potent (see compounds 21, 22, 24). The use of alkyl-amino linkers of different 
length gave compounds with very little actives (see compounds 25, 26, 27, 28). The nitrogen 
alone linking the two rings was not much active as well (see compound 29). The best 
compound was the sterically hindered isoindoline derivative (see compound 30) with an IC50-
value of 73 nM. The branched compound 31 (racemic mixture) was less active. From these 
selected examples it is clear that a replacement of the sulfonamidomethylen linker can be 
performed only at the cost of the high anti-P. falciparum activity.  
 
Table 3.4: Anti-P.falciparum activity of SC81458 analogues, with different tethering groups 
linking ring B and C. 
 
 
  
N° Structure of the tether IC50 
(µM) 
19  1 
20  2.17 
21  0.168 
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22  0.732 
23  0.266 
24  0.217 
25  2.18 
26  ND 
27  1.44 
28  2.53 
29  4.1 
30  0.073 
31  0.224 
32  1.71 
 
 
Results 
 56
Few analogues were synthesized to verify the influence of the urea linker between phenyl rings 
A and B to the anti-P. falciparum activity of the parent compound SC81458. As table 3.5 
indicates, a simple replacement of a –NH– group with the isosteric –CH2– group (see 
compound 33) caused a significant decrease of anti-P. falciparum activity (174-fold less active 
than SC81458), confirming the important role of this hydrogen-bond donor group. Meanwhile, 
a shorter analogue (see compound 35) or scrambling the carbonyl and amino group (see 
compound 34) were also not tolerated. 
 
Table 3.5: Activity of the urea modified analogues of SC81458 vs P.falciparum. 
 
N° Structure of the tether IC50 (µM) 
33  0.87 
34  7.16 
35  0.372 
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A series of SC81458 west side analogues were designed and synthesized by 4SC to study the 
SAR of the west side of SC81458. As table 3.6 indicates, no compounds showed the same anti-
P.falciparum as SC81458, which suggests that the presence of additional nitrogens seems to be 
crucial for a high anti-P.falciparum activity. 
 
Table 3.6: Anti-P. falciparum activity of the west side analogues of SC81458. 
 
 
N° Benzamidine IC50 (µM) 
  SC81458 0.0055 
36  0.39 
37  ND 
38  0.278 
39  0.165 
40  0.149 
41  0.041 
42  0.995 
N
NH
S
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43  0.176 
44  0.089 
45  0.146 
46  0.034 
47  0.496 
48  0.201 
 
Results 
 59
The SAR study on the west side of SC81458 focused on the piperazine-containing west side 
analogues for more detailed information. As expected, some of the analogues exhibited 
excellent anti-P.falciparum activity, even more potent than SC81458 (table 3.7). The results 
indicated that the size of the carbon chain and the amidine are closely associated with the anti-
P. falciparum activities of this series of compounds. Furthermore, acylation or carbamoylation 
of the piperazine nitrogen analogs exhibited comparable or even more potent anti-P. 
falciparum activities than the parent compound (see compound 60, 62, 63). 
 
Table 3.7: Anti-P. falciparum activity of the piperazine-containing west side analogues of 
SC81458. 
H
N
H
N
O S
NH
N
N
O
O
N
H
S
O
O
NH2
A B
C
 
N° Piperazine structure IC50 (nM) 
  SC81458 5.5 
49  75 
50  75 
51  277 
52  25 
53  7 
54  38 
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55  13 
56  196 
57  5420 
58  100 
59  25 
60  3.8 
61  25 
62  2.8 
63  4.4 
64  12 
65  606 
 
 
These data together with the ADMET properties (provided by 4SC) were used for the SAR 
study of SC81458, which eventually led to the discovery of SC83288. The discovery of 
SC83288, a sulfnamidomethylen compound with better bioavailability and anti-P. falciparum 
N
NH
N
O
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activity than SC81458, is an excellent example for SAR successfully directing drug 
optimization. 
3.4 Parasitological evaluation of SC81458  
We found many compounds that showed in vitro anti-P. falciparum activity. However, it does 
not mean all of them would become anti-P. falciparum drugs. Actually, only very few of the 
active anti-P. falciparum compounds are being selected as candidate compounds for future 
development. Above all, the active compound should showed good ADMET properties. 
Otherwise, it is impossible for this compound to become a candidate compound for further 
study. Furthermore, the active compound must exhibit good parasitological properties, such as 
failure to induce drug resistance under in vitro conditions, activity against several parasite 
stages and a fast killing speed etc. The work of 4SC indicated that SC81458 exhibit ideal 
ADMET properties. The parasitological evaluation of SC81458 was performed as follows. 
An excellent anti-P. falciparum drug should be efficious against a broad range of P. falciparum 
strains. As Fig 3.5 indicates, SC81458 showed excellent in vitro activity against blood stages 
of the P. falciparum clone Dd2.  
Table 3.8: The IC50-values (nM) of SC81458 and the other licensed anti-P. falciparum drugs 
against different P. falciparum strains. All data were from three independent experiments. 
P.falciparum 
strains 
SC81458 Chloroquine Quinine Mefloquine Halofantrine Quinidine Pyrimethamine Amodiaquin Artemisnin 
Dd2 5,5±1,3 70,5±12,1 124,1±25,2 1,3±0,1 16,8±4,7 37,4±7,8 >15000 6,8±1,4 5,0±0,3 
D10 9,1±3,5 11,4±3,2 58,2±5,1 3,5±0,1 31,7±4,6 15,8±1,2 10,5±1,6 7,1±1,5 8,5±0,4 
3D7 12,5±3,9 2,9±0,7 13,7±2,1 3,7±0,6 19,8±2,2 14,2±1,1 15,8±2,8 7,8±1,1 7,7±0,3 
FCR3 13,1±7,9 25,3±4,2 182,2±27,4 1,2±0,2 7,0±1,5 32,4±6,4 31,3±7,8 7,6±0,4 5,0±0,9 
K1 9,4±2,9 69,7±14,1 46,2±4,1 1,2±0,1 5,1±1,4 11,8±2,7 >15000 9,2±0,9 3,3±0,8 
Thai19 7,4±1,3 74,1±17,1 62,2±10,0 1,1±0,1 4,3±0,7 21,5±5,1 >15000 8,5±0,8 2,8±0,5 
7G8 18,4±4,5 30,2±7,3 69,1±17,3 0,2±0,1 2,7±0,5 15,9±3,9 >15000 7,4±1,9 1,1±0,3 
 
As Tab. 3.8 shows, SC81458 exhibited excellent in vitro anti-P. falciparum activities against 
seven P. falciparum strains, which were derived from different endemic areas and which 
showed different drug sensitivities to established anti-malarial drugs. The IC50-values ranged 
from a few nanomolar to less than 20 nM. The multi-drug resistant strains, such as Dd2, K1 
and Thai19, were significantly more sensitive to SC81458 than were the drug-sensitive strains 
investigated (P< 0.05). The results indicated that SC81458 killed a wide range of P. falciparum 
strains, irrespectively of their drug resistance phenotypes. 
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3.4.1 Stage-specific activity of SC81458 
To further study the anti-P. falciparum activity of SC81458, I evaluated the activity of 
SC81458 against different P. falciparum blood stages. Highly synchronized cultures of Dd2 
containing rings (2-4 hrs post invasion), trophozoites (24-26 hrs post invasion) and schizonts 
(35-37 hrs post invasion) were exposed to different concentrations of the compound for six hrs. 
The parasites were subsequently washed twice and transferred to drug-free medium. [3H]-
hypoxanthine was added at 54 hrs to monitor parasite viability. The IC50-value of SC81458 
against the different P. falciparum blood stages was used to evaluate the stage-specific 
susceptibility of this compound. Under these conditions, SC81458 exerted the highest activity 
against trophozoites, with an IC50-value of 36.9 nM (Fig. 3.7A). A comparable, but slightly 
lower activity was observed against schizonts, with an IC50-value of 53.7 nM (Fig. 3.7). The 
activity against ring stages was only moderate, with an IC50-value of around 5 µM (Fig 3.7). 
The data indicated that SC81458 exhibits a stage-specific activity against P. falciparum. 
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Fig. 3.7: Stage Specific activity of SC81458 against P. falciparum 
SC81458 was added at various concentrations to synchronized parasites in culture at ring stage (2-4 
hrs), trophozoite stage (24-26 hrs) and schizont stage (35-37 hrs). Incubation was continued for 6 hrs, 
cells were washed twice and resuspended in fresh complete medium. [3H]-hypoxanthine was added at 
54 hrs to monitor parasite viability. Reactions were stopped at 78 hrs, and parasitemia were evaluated 
for each stage and expressed as a percentage of the control (without drug). The data represent the means 
± SEM of three independent determinations. 
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3.4.2 Time course of growth inhibition 
The killing speed of an anti-P. falciparum drug is a very important property for the drug, since 
it is closely related to the clinical efficacy. Furthermore, it also relates to the emergence of drug 
resistance. A drug, such as artemisinin, that quickly kills the parasites, quickly decreases the 
number of the in vivo parasite, i. e. only few or even no parasites have a long term exposure to 
the drug. In turn, the possibility for the emergence of drug resistance would be reduced. 
Additionally, killing speed and PK property are crucial parameters of drug dosage. To assess 
how quickly SC81458 is able to kill the parasite, we exposed highly synchronized cultures of 
Dd2 containing rings (2-4 hrs post invasion), trophozoites (24-26 hrs post invasion) and 
schizonts (35-37 hrs post invasion) to different concentrations of SC81458 (ranging from 0.1 to 
10 µM). The parasites were washed twice and transferred to drug-free medium at different time 
point. Then [3H]-hypoxanthine was added at 54 hrs (counted post invasion of the first 
replication cycle) to monitor parasite viability. As depicted in Fig. 3.8 A, B and C, SC81458 
killed trophozoites and schizonts within hours after exposure. For example, at a concentration 
of 500 nM, 100 % of the trophozoites and 100 % of the schizonts were dead within 1 hr and 5 
hrs, respectively. At 100 nM, the lowest concentration tested, almost 80 % of the trophozoites 
and 40 % of the schizonts were killed within the first hour.  
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Fig. 3.8: The killing speed of SC81458 against P. falciparum at different blood stages.  
SC81458 was added at 100 nM, 500 nM, 1 µM, 5 µM, 10 µM to synchronized cultures at ring stage (2-
4 hrs), trophozoite stage (24-26 hrs) and schizont stage (35-37 hrs), respectively. After incubation for 
the times indicated, cells were washed twice and resuspended in fresh complete medium. [3H]-
hypoxanthine was added at 54 hrs to monitor parasite viability. Reactions were stopped at 78 hrs, and 
parasitemia were expressed as a percentage of the control (without drug). The data represent the means 
± SEM of three independent determinations. 
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The parameter of t1/2 is a constant to evaluate the killing speed of anti-infectious drugs, which 
means the time it takes for an anti-infectious drug to kill half of the pathogens at a certain 
concentration. The t1/2 could be used as a standard to compare the killing speed between 
different drugs. As expected, the t1/2 curves declined with increasing concentrations of 
SC81458. 
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Fig. 3.9: The Killing t1/2 of SC81458 against P. falciparum at different stages. 
SC81458 was added at 100 nM, 500 nM, 1 µM, 5 µM, 10 µM to synchronized cultures at trophozoite 
stage (24-26 hrs) and schizont stage (35-37 hrs). After incubation for the times indicated, cells were 
washed twice and resuspended in fresh complete medium. [3H]-hypoxanthine was added at 54 hrs to 
monitor parasite viability. Reactions were stopped at 78 hrs, and parasitemia was expressed as a 
percentage of the control (without drug). Then the data were fit to exponential decrease equation to 
calculate t1/2. All data were from three independent experiments.  
 
The result of the time course study is consistent with the stage specific study (Fig 3.7 and Fig 
3.8).  
3.4.3 Drug resistance inducing property of Dd2 
The emergence of drug resistance means a decrease or even loss of responsitiveness. Therefore, 
drug candidate should not be able to induce drug resistance. The drug resistance property of 
SC81458 was determinated based on the standard protocol of Rathod et al (Rathod et al., 1997). 
Different inoculating number of Dd2 parasites were exposed to SC81458 (100 nM) for eight 
weeks. At the same time, 5-fluoroorotate was used as a positive control. 5-fluoroorotate was 
chosen as a positive control owing to the fact that its IC50-value is comparable to that of 
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SC81458 (approximately 5 nM). Parasites were cultured by standard methods in the presence 
of 2% hematocrit with medium changes three times per week. In addition, cultures were split 
1:2 with fresh erythrocytes once a week. Slides were prepared from every flask with each 
medium change and stained with Giemsa to test for the emergence of parasites. Ten parasites 
in one plate (3 replicates) were used as the control for parasite culture. As Tab 3.9 indicates, all 
the parasite culture controls grew up within three weeks in the absence of drugs (data not 
shown). Parasites recovered in the drug-resistance positive control plates, where 108 parasites 
were exposed to 5-fluoroorotate at the concentration of 100 nM. No parasites recovered in all 
the plates exposed to SC81458, which indicated Dd2 could not develop in vitro resistance to 
SC81458 at the concentration of 100 nM.  
 
Table 3.9: Drug resistance inducing property of Dd2. 
 
3.5 The further optimization of SC81458 for better activity 
and ADMET properties 
SC81458 showed many excellent anti-P. falciparum drug properties. However, the 
bioavailability of SC81458 was found to be poor (4SC unpublished data). As part of new round 
of SAR analysis, 4SC synthesized a series of derivatives, one of the derivatives, compound 
SC83288, turned out to have a very potent anti-P. falciparum activity, with an IC50-value of 3.8 
nM (Fig 3.10). As described for SC81458, I evaluated the stage-specific activity, the killing 
speed, the in vitro activity against a panel of different P falciparum strains and the possibility 
of inducing resistance under in vitro culture condition (This experiment is still ongoing). 
Inocculating number of parasite 105 106 107 108 
SC81458 (100 nM / 8 weeks) --- --- --- --- 
5-Fluoroorotate (100 nM / 8 weeks) --- --- --- +++ 
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Fig. 3.10: The dose-response curve of SC83288 against P. falciparum. The data represent the 
means ± SEM of three independent determinations. 
 
As Tab. 3.10 indicates, the seven P. falciparum strains examined were sensitive to SC83288, 
with IC50-values ranging from 3 nM to 10 nM.  
 
Table. 3.10: The activity of SC83288 against different P. falciparum strains. All data were from 
three independent determinations. 
P.falciparum strains IC50-values 
  
Dd2 3,8 ± 0,5 
D10 5,3 ± 0,5 
3D7 8,2 ±2,0 
FCR3 6,4 ± 0,5 
K1 4,9 ±0,8 
Thai19 3,9 ± 0,8 
7G8 10,2 ±0,5 
 
Both SC81458 and SC83288 belong to the same subclass of sulfnamidomethylen compounds. 
SC83288 revealed the same stage specific activity as did SC81458, i.e., trophozoites and 
schizonts were more sensitive to SC83288 than were rings, with IC50-values of 23.8 nM, 124.8 
nM, and 2968.3 nM, respectively. In terms of the killing speed, SC83288 killed 90% of the 
trophozoite and the schizonts within 6 hrs at a concentration of 100 nM and 500 nM, 
respectively. The killing speed against rings was lower. 60-80% of the rings were killed after 6 
hrs at a concentration of 10 µM. 
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Fig. 3.11: Stage Specific evaluation of SC83288 to Dd2. 
SC83288 was added at various concentrations to synchronized parasites in culture at ring stage (2-4 
hrs), trophozoite stage (24-26 hrs) and schizont stage (35-37 hrs). Incubation was continued for 6 hrs, 
cells were washed twice and resuspended in fresh complete medium.[3H]-hypoxanthine was added at 54 
hrs to monitor parasite viability. Reactions were stopped at 78 hrs, and parasitemia were evaluated for 
each stage and expressed as a percentage of the control (without drug). The data represent the means ± 
SEM of three independent determinations.  
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Fig. 3.12: The killing speed of SC83288 at different concentrations against P. falciparum at ring 
stages. 
SC83288 was added at 100 nM, 500 nM, 1 µM, 5 µM, 10 µM to synchronized cultures at ring stage (2-
4 hrs), trophozoite stage (24-26 hrs) and schizont stage (35-37 hrs), respectively. After incubation for 
the times indicated, cells were washed twice and resuspended in fresh complete medium. [3H]-
hypoxanthine was added at 54 hrs to monitor parasite viability. Reactions were stopped at 78 hrs, and 
parasitemia were expressed as a percentage of the control (without drug). The data represent the means 
± SEM of three independent determinations. 
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The t1/2-values obtained for SC83288 were comparable to those of SC81458.  
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Fig. 3.13: The Killing t1/2 of SC83288 against P. falciparum at different stages. 
SC83288 was added at 100 nM, 500 nM, 1 µM, 5 µM, 10 µM to synchronized cultures at Trophozoite 
stage (24-26 hrs) and Schizont stage (35-37 hrs). After incubation for the times indicated, cells were 
washed twice and resuspended in fresh complete medium. [3H] hypoxanthine was added at 54 hrs to 
monitor parasite viability. Reactions were stopped at 78 hrs, and parasitemia was expressed as a 
percentage of the control (without drug). Then the data were fit to exponential decrease equation to 
calculate t1/2.  
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As Fig 3.14 indicated, the SC81458 resistant Dd2 strain also showed cross-resistance to 
SC83288, the IC50-value increased almost 15 fold as compared to parental Dd2 strain. It is 
possible that SC83288 interacts with the same target as does SC81458. Furthermore, the 
positive correlation (r2=0.91) between the IC50-values of SC81458 and SC83288 against the 
seven P. falciparum strain suggests that the two compounds exert their action by the same 
mechanism (Fig. 3.15).  
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Fig. 3.14: The dose-response curve of SC83288 against P. falciparum (Ring) and SC81458 
resistant Dd2 (Square).  
Dd2 cultures (108 infected erythrocytes/10ml/plate) were exposed to 50 nM of SC81458. Parasites were 
cultured by standard methods in the presence of 2% hematocrit with medium changes three times per 
week. In addition, cultures were split 1:2 with fresh erythrocytes once a week. Slides were prepared 
from the plate with each medium change and stained with Giemsa to test for the emergence of parasites. 
Dd2 parasite recovered 38 days post-challenge. The strain was transfered to drug free medium and 
assayed using the standard cell proliferation assay.  
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The IC50-values of SC83288 against different P. falciparum strains
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Fig. 3.15: The correlation between the IC50-values of SC83288 and SC81458 against different P. 
falciparum strains. 
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4 Discussion 
My data show that SC81458 and SC83288 represent a new class of compounds with potent 
activity against P. falciparum blood stages. The compounds are highly active against 
trophozoites and schizonts, with IC50-values in the lower nano-molar range. Moreover, 
they are able to kill the parasite within less than one hour of exposure.  
SC81458 and SC83288 were developed from the same lead compound of biphenyl urea. 
During the initial phase of our project, a large number of virtual compounds were designed 
as inhibitors of the Plasmodium falciparum lactate dehydrogenase (PfLDH) based on the 
structure of PfLDH and screened virtually by 4SC using docking experiments (Leban et 
al., 2004), which was based on the consideration and calculation of the interaction energy, 
hydrogen bonding and solvation energy changes. Presently, target-based drug design is an 
important approach for anti-P. falciparum drug development. PfLDH, structurally and 
functionally different from the human host isozymes, is an essential enzymes of 
Plasmodium falciparum. Furthermore, the crystal structure of PfLDH is available. 
Therefore, PfLDH is a potential drug target for the development of novel anti-malarials.  
The in silico approach identified the biphenyl urea compounds as a novel structural class of 
potent anti-malarial agents. However, the inhibition activity of this class of compounds 
against the PfLDH enzyme was very low, which means this class of compounds kill P. 
falciparum parasites through another unknown mechanism (Leban et al., 2004). Therefore, 
we changed our strategy and used cell based compound screening for further development. 
This approach tests the anti-malarial activity of compounds by the killing action to the 
parasites directly. Actually, many anti-malarial drugs, such as mefloquine, halofantrine and 
artemisnin, were developed by this approach. As the screen was based on the cell level, the 
target of the biphenyl urea compounds remained unknown when we obtained them. So it is 
impossible for us to get any information on the target.  
The SAR study on diarylureas compounds was driven to guide further optimization, which 
would establish effective predictive models based on the experimental data (Fig. 3.1) and 
the information on essential chemical requirements for biological activity. This work was 
based on the assumption that all the tested analogues interact with the same target in the 
parasite. The substituent parameters from physical chemistry were used to correlate 
chemical properties with biological activity to provide important directions for the next 
round of optimization. Until now, we have finished 14 rounds of screen and optimization, 
with more than 300 compounds tested (data not shown). With the assistance of the SAR 
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study, we obtained the first generation of diarylureas antiparasitic compounds, a class of 
sulfonamido-phenyl-ureido benzamidine compounds. With further optimization of the 
sulfonamido-phenyl-ureido benzamidine compound, two subclasses of active compounds, 
sulfnamidomethylen and diarylsulfone, were obtained.  
As Fig 3.2 indicates, the two subclasses of novel anti-P. falciparum compounds exerted 
their action by different mechanisms. The dose-response curves of diarylsulfone 
compounds showed a biphasic behavior, which means these compounds might interact 
with different targets or interact with the same target with different forms of post-
translational modification during the whole blood stages. The binding of the diarylsulfone 
compound with a high affinity target (or high affinity target form) would block parasite 
growth and the binding with lower affinity (or low affinity target form) would kill the 
parasites. However, the results of Fig 3.3 indicated that there are different targets even in 
the same blood stage. Furthermore, the sulfnamidomethylen resistant Dd2 did not show 
any resistance to the diarylsulfone compounds (Fig. 3.3), which indicated that the two 
subclasses of compounds kill parasites by different mechanisms. The single phasic 
property of the dose-response curve of sulfnamidomethylen indicated that this class of 
compounds interact with a single target in all the erythrocytic phase stages. The 
sulfnamidomethylen compound was further optimized for more potent anti-malarial 
activity and better pharmacokinetic properties. Finally, we obtained SC81458 and 
SC83288, which showed the best anti-P. falciparum activity (Fig 3.5 and 3.10).  
SC81458, which was first obtained, showed excellent in vitro anti-P. falciparum activity 
and good ADMET properties. Then a very accurate SAR study on SC81458 was performed 
by 4SC, which focused on the relationship between chemical structures and ADMET 
properties / anti-Plasmodium activity of this compound. Based on the SAR study on 
diarylureas compounds, the structure of SC81458 was divided into three regions (Fig. 3.6) 
and each one of them was investigated, introducing tailored structural variations. Few 
structural features of SC81458 were maintained unaltered; for example the phenyl rings A 
and B with the 1, 3 and 1’, 4’ functionalized positions. As tables 3.2, 3.3, 3.4, 3.5, 3.6 and 
3.7. indicated, the anti-P. falciparum activities of four different blocks of compounds were 
determined, which include short fragments, variation to the sulfonamidomethylen group at 
the east-side, variations at the urea bridge and variations at the functionalized amidine 
group at the west-side. Furthermore, the ADMET properties of all the compounds above 
were evaluated. Then, all the data on ADMET and anti-Plasmodium activity were 
combined together for SAR analysis. The results indicated that the rings in SC81458 are 
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fundamental to preserve the high activity. The functionalized positions of the rings are also 
essential for the high activity. Both the east and west side of SC81458 are necessary for 
anti-plasmodium activity. Even a smaller loss of the molecular structure would cause a 
decrease in anti-P. falciparum activity (table 3.2). The east-side ending sulphonamide was 
maintained as substituent group of phenyl ring C, which is necessary to confer the 
characteristic steepness to the dose-response curves of this class of compounds. Analogues 
bearing different substituents at this position showed more flat dose-response curves than 
SC81458. The size of the carbon chain and the amidine in the west side are closely 
associated with the anti-P. falciparum activities of the analogues. Acylation or 
carbamoylation of the piperazine nitrogen analogs even exhibited more potent anti-P. 
falciparum activities than SC81458 (table 3.7). Furthermore, the sulfonamidomethylen 
linker of SC81458 is involved in the metabolic stability of the compound (4SC 
unpublished data), which is closely related to the PK property of SC81458. The PK data of 
SC81458 (not shown) indicated that the metabolic stability of this compound should be 
improved in the further optimization for better in vivo activity. However, the results 
indicated that all the alterations of the sulfonamidomethylen linker would cause a loss of 
high anti-P. falciparum activity to SC81458 (table 3.4). The SAR study of SC81458 
provided crucial direction for further optimization of the sulfnamidomethylen compound. 
The successful discovery of SC83288, which showed significantly improved 
bioavailability and slightly better anti-Plasmodium activity than SC81458 does, is 
powerful evidence for the direct effect of the SAR study. Bioavailability is an important 
ADMET property of a drug, which is used to describe the fraction of an administered dose 
of unchanged drug that reaches the systemic circulation. Good bioavailability is crucial for 
a promising anti-Plasmodium candidate drug as the drug is expected to be orally 
administered in a poor country. The discovery of SC83288 caused important progress in 
the development of the sulfnamidomethylen compound. 
As a novel class of anti-Plasmodium compounds, SC81458 and SC83288 exhibited 
excellent activities against a wide range of P. falciparum strains. As table 3.8 and 3.10 
showed, seven P. falciparum strains isolated from different epidemic regions were used for 
the in vitro activity evaluation, which included Dd2, 3D7, D10, K1, FCR3, 7G8 and 
Thai19. The seven P. falciparum strains exhibited different sensitivities to the commonly 
used anti-P. falciparum drugs, including chloroquine, quinine, mefloquine, halofantrine, 
quinidine, pyrimethamine, amodiaquin, artemisnin (table 3.8). However, all the IC50-values 
of SC81458 and SC83288 against the seven P. falciparum strains are in the same nano 
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molar range. Dd2, K1 and Thai19 are of high-level chloroquine resistance among the seven 
strains. However, the three chloroquine resistant strains were significantly more sensitive 
to SC81458 and SC83288 than were the other chloroquine sensitive strains (P<0.05). Thus, 
sulfnamidomethylen compound may become a promising substitute for some of the 
presently used drugs against which resistance has emerged. Furthermore, there is a strong 
correlation between the IC50-values of SC81458 and SC83288 against the seven P. 
falciparum strains, suggesting that the two compounds interact with the same target in the 
seven strains and that the difference in IC50-values between the two compounds is caused 
by a different binding affinity to the target. Meanwhile, there is no significant correlation 
between the IC50-values of sulfnamidomethylen compounds and the other drugs tested, 
suggesting sulfnamidomethylen compounds exert their anti-P. falciparum action by a 
novel mechanism  
A good anti-malarial drug should cure this disease with once or twice a day dosing within a 
maximum of three-day therapy, which means the drug should be able to kill the parasites in 
different blood stages very quickly. Otherwise, some parasites might escape from the 
therapy and reach the next life cycle, which would cause a failure of three-day therapy. As 
Fig 3.7 and 3.11 indicated, the trophozoites and schizonts are very sensitive stage to the 
two compounds, with 6 hrs IC50-values around 30 nM and 100 nM, respectively. However, 
the rings exhibit the IC50-values against the two compounds in a micromolar range. The 
result of the time course study is consistent with the stage specific study (Fig 3.8 and Fig 
3.12). The killing speed of SC81458 and SC83288 against the trophozoites is the fastest 
among the three stages, which is close to artemisinin dose (data not shown). Additionally, 
the killing speed against schizont stage is faster than that against ring stage. The rings can 
be killed by more than 60% in 6 hrs by SC81458 or SC83288 only at the concentration of 
10µM. However, the lowest concentration of SC81458 or SC83288 is able to kill schizont 
stages by more than 90% in 6 hrs between 100 and 500nM, and even less than 100nM in 
trophozoite stages. The same phenomenon is seen for chloroquine. Actually, this is a very 
common phenomenon for most anti-malarial drugs as trophozoites and schizonts are more 
metabolically active than rings (Tamez et al., 2005). Only few drugs, such as artemisinin 
and TE3 (Schlitzer, 2008; Vial et al., 2004), showed activity against all the blood stages of 
Plasmodium falciparum. However, no anti-malarial drug could be used alone due to drug-
resistance. We can design a combination for SC81458 or SC83288 based on the data of 
stage-specificity. The combined drugs would show activity against all the blood stages of 
Plasmodium falciparum and exhibit more efficacy against malaria. 
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The quick clearance of SC81458 and SC83288 against the trophozoites and schizonts 
indicates that the number of parasite will decrease significantly in one life cycle or less 
time. There would be few of or even no parasites exposed to the anti-Plasmodium drug, 
which means a less opportunity for the parasites to develop resistance to this drug. 
Furthermore, the time course of Plasmodium falciparum growth inhibition and the stage-
specific susceptibility study would also provide important data for future clinical use of the 
two compounds, such as the dosage regimen and the combination protocol with the other 
anti-malarial drugs. We can design a rational combination protocol for SC81458 or 
SC83288 with the other licensed anti-malarial drugs based on the data above. P. 
falciparum parasites at both trophozoite and schizont stages are sensitive to SC81458 or 
SC83288, which suggests that the two candidate drugs should be combined with a rings-
sensitive drug, such as artemisinins or T3. Then the combination would show better killing 
speed against the parasites in different blood stages, which is crucial against the drug 
resistance selection. 
As death by severe malaria usually occurs within 48 hours of presentation, equal to the 
time for one asexual cycle of the blood-stage infection, so the anti-P. falciparum drugs 
must kill the current generation of P. falciparum malaria parasites and decrease the amount 
of parasites emergent in the next cycle. Parasite killing by anti-malarial drugs is a first-
order process, which leads to a log-linear reduction in parasite numbers with time. 
Uninhibited blood-stage multiplication at 100% efficiency results in a parasite 
multiplication rate (PMR) equal to the median number of viable merozoites liberated by 
rupturing schizonts. In vivo efficiencies may exceed 50% in nonimmune patients, resulting 
in PMRs of approximately 10 per asexual cycle. Anti-malarial drugs convert this positive 
value to a negative value, resulting in PMRs that range between 10–1 and 10–4 per cycle. 
These negative PMRs are also termed parasite killing rates or parasite reduction ratios, 
which depend on the killing speed and the concentration of the anti-malarial drug and the 
time of parasite exposure to the drug. We can model the clinical action for the 
sulfnamidomethylen compound. With clinical presentation, the parasites start a new life 
cycle in the body of severe malarial patients. Then the patient presents to a clinician and is 
prescibed SC81458 or SC83288. As this class of compound is less toxic, the in vivo 
concentration would reach the magnitude of micro molar. When the drug was absorbed by 
the body, the present stage of the parasite should be late ring or trophzoite, even schizont. 
As Fig 3.7 and 3.12 indicates, the sensitive stages of the P. falciparum to the compound are 
trophozoite and schizont stage, with a 6 hours exposure IC50-value of less than 100nM, 
Discussion 
 77
which means the parasite stage matched with the stage-specificity of drug action. 
Otherwise, most of the parasites go through to the next cycle and the parasite number will 
increase more than ten-fold, which will cause the death of the patient. Even if the patient 
take the drug very late in this life cycle (late schizont stage), the drug still could kill more 
than 80 percent in 4 hours at a concentration of 500 nM. So the patient should be alive 48 
hours post clinical presentation. The quick action of such an anti-malarial drug means more 
hope for the survival of the severe malaria patient. For the uncomplicated malaria patient, 
inhibition of parasite multiplication has greater importance, as this prevents the progression 
to severe disease and leads to resolution of fever and other symptoms. Meanwhile, the 
combination of the sulfnamidomethylen with artemisinins or other rings sensitive drugs 
should provide more efficacious therapy against malaria. However, much work should be 
performed for the use of the sulfnamidomethylen in combination with other drugs, such as 
PK, and toxicity evaluation on the combined drugs. 
The property against drug resistance selection is one of the most crucial properties of an 
anti-malarial drug, which could be conferred by special enzymes or transporters. Most 
resurgences of malaria are caused by drug resistance. Widespread drug resistance is also an 
important reason for the increase of malarial infection. Artemisinin and chloroquine are 
excellent in this aspect. However, pyrimethamine and sulfadoxine were poor against drug 
resistance selection. The emergence of drug resistance means the decrease or even loss of 
anti-malarial efficacy of a drug. So this property is a fatal factor for the future development 
of a novel anti-malarial compound. As table 3.9 indicates, SC81458 can totally clear Dd2 
with a number ranging from 105 to 108 at the concentration of 100nM without parasite 
recovery or drug resistance emerging within eight weeks. Even in drug free medium, no 
parasite could be seen in the following two weeks. As reported, many of the presently used 
anti-P. falciparum drugs such as quinine, chloroquine, amodiaquine, pyrimethamine, 
sulfadoxine, atovaquone and artemisinin derivatives are compromised by resistance. The 
mechanisms behind malaria drug resistance mainly include drug target mutation, drug 
transporter up-regulation or mutation (Fidock et al., 2000; Sanchez et al., 2005) and 
mutations/up-regulation of enzymes metabolizing the drug (Uhlemann et al., 2005; 
Yuvaniyama et al., 2003). Additionally, cross-resistance between different drugs is 
occasionally present. Thus, rational combination of different drugs is an important strategy 
to overcome drug resistance. So the next step is to combine the sulfnamidomethylen with 
other anti-P. falciparum drug based on the data of stage specificity, drug target and PK 
property. 
Discussion 
 78
In vivo efficacy is the one of the most important aspects in the pre-clinical phase of drug 
development, which can decide if the project will go ahead, backtrack or even be canceled. 
The data from the in vitro study could not provide all the information for the in vivo action 
of the drugs, such as the binding of drugs with plasma protein, which will influence the in 
vivo efficacy. There is sometimes a significant difference between in vitro and in vivo 
activities for some drugs. The in vivo study of the sulfnamidomethylen showed that 
SC81458 is active against P. vinckei at 30 mg/kg (ip) (data not shown). The parasitemia 
decreased more than 90% in comparison with controls after four days daily ip at 30 mg/kg. 
However, SC81458 showed no in vivo efficacy against the murine parasite P. berghei at a 
concentration of 30 mg/kg (ip) (data not shown), which indicated that there is a species 
specificity for the anti-P. falciparum activity of SC81458. Further in vivo efficacy 
evaluation was performed in humanized mice (multiple dose study), which were infected 
with the human parasite P. falciparum, 3D7 and W2 (CQ sensible and resistant, 
respectively) (data not shown). The results indicated that SC81458 showed an excellent in 
vivo therapy efficacy in the humanized mice model. Both the two strains of parasites were 
totally clear within 3 days by once-daily ip (5 mg/kg) injection. Parasite clearance even 
occurred within 2 days at a dosage of 10 mg/kg. A good anti-malarial drug should be able 
to cure this disease within three days with dosing once or twice a day. It is very crucial for 
the delay of the drug resistance development. Furthermore, the sulfnamidomethylen is very 
easy to be synthesized at a low cost, which is nontrivial for anti-malarial drugs as these 
drugs would be used in many developing countries.  
As a novel anti-malarial candidate drug, the sulfnamidomethylen exhibited many excellent 
properties, such as excellent in vivo activity with quick action, good ADMET properties, a 
broad spectrum, excellent property against drug resistance selection and low cost. Next, we 
should design a rational combination for the sulfnamidomethylen based on the data of PK, 
action mechanism, toxicity and the stage-specific properties.  
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